Nano-delivery system and therapeutic and diagnostic use thereof
Patent Information
- Application Number
- HK62023075800
- Authority / Receiving Office
- HK · HK
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-03-15
- Filing Date
- 2023-07-11
- Publication Date
- 2026-09-04
- Estimated Expiration
- 2041-03-14
AI Technical Summary
Existing technologies have difficulty effectively penetrating the blood-brain barrier (BBB) to deliver drugs to the brain, especially for large and low molecular weight drugs.
A nanodelivery system was designed that couples inorganic nanoparticles with brain-mediated transport protein components via first and second polymeric linkers. The system utilizes the different lengths and indivisibility of the polymeric linkers to improve penetration efficiency while maintaining drug activity.
It achieves efficient BBB penetration of various types of drugs, maintains drug activity, and is suitable for the treatment and diagnosis of a wide range of brain-related diseases.
Smart Images

Figure 00000042_0000 
Figure 00000042_0001 
Figure 00000043_0000
Abstract
Description
Technical Field
[0001] This invention belongs to the field of brain-targeting nanodelivery systems for therapeutic and diagnostic purposes. Background Technology
[0002] A key challenge in treating neurodegenerative disorders and diseases is the difficulty in overcoming the blood-brain barrier (BBB) to deliver essential therapeutic and diagnostic agents to the brain. The BBB is a highly selective, semi-permeable boundary that separates circulating blood from the central nervous system (CNS). The BBB primarily functions as a protective barrier for the brain, preventing a wide variety of substances, including hormones, neurotransmitters, and neurotoxins, from entering the CNS from the bloodstream. Although specific and selective transporters located on the BBB provide the CNS with glucose, free fatty acids, amino acids, vitamins, minerals, and electrolytes, almost all high-molecular-weight drugs and over 98% of low-molecular-weight drugs cannot cross the BBB.
[0003] To overcome the limitations associated with the BBB, various nanomaterial-based drug delivery systems are being developed.
[0004] US 10,182,986 relates to a method of delivering nanoparticles across the blood-brain barrier to the brain of a subject by administering nanoparticles having a nanoparticle core and a targeting agent to the subject.
[0005] Ruan, Shaobo et al. (Biomaterials 37(2015):425-435) provided a gold nanoparticle-based delivery system that loads doxorubicin (DOX) via an acid-responsive linker called hydrazone and is functionalized with angiopep-2, a specific ligand of low-density lipoprotein receptor-associated protein-1 (LRP1). This enables the system to penetrate the blood-brain barrier and target glioma cells.
[0006] Shilo, Malka et al. (Nanoscale 6.4(2014):2146-2152) discussed the transport of insulin-targeting gold nanoparticles (INS-GNP) across the blood-brain barrier for imaging and therapeutic applications.
[0007] There remains an unmet need for efficient systems for transporting therapeutic and / or diagnostic agents across the BBB and delivering them into the brain. A universal platform capable of delivering a wide variety of drugs into the brain is highly desirable. Summary of the Invention
[0008] This invention provides a universal platform for delivering molecules with low blood-brain barrier (BBB) penetration into the brain. The delivery system is based on a core nanoparticle coupled to brain-internalized transporter components via a first polymeric linker and further coupled to a second polymeric linker capable of binding therapeutic or diagnostic agents of interest. Therefore, the delivery system of this invention can be used to treat and / or diagnose a wide range of brain-related diseases or disorders.
[0009] The inventors of this invention have demonstrated that various types of molecules with poor BBB penetration, including antibodies, peptides, and small molecules, can efficiently penetrate into the mouse brain when conjugated to the delivery system of this invention, wherein the core nanoparticles are gold nanoparticles (GNPs) or iron oxide nanoparticles, and the brain-internalized transporter components are insulin or transferrin. This invention is based in part on the surprising discovery that the relative lengths of the first and second polymeric linkers have a critical influence on the BBB penetration of the delivery system. Specifically, it was unexpectedly found that when insulin and antibodies were conjugated to the core nanoparticles using polymeric linkers of different sizes, efficient BBB penetration of GNPs conjugated to insulin and the antibodies was achieved. It was further surprising to find that the relative amount of linkers used for antibody conjugation affects the efficiency of the delivery system's penetration into the brain.
[0010] One of the advantageous features of the delivery system of the present invention is that the activity of the therapeutic agent coupled to the delivery system remains intact, so that it does not need to be detached from the nanoparticle after crossing the BBB, for example, by using a cleavable linker. Specifically, it has been unexpectedly found that antibodies bound to the nanodelivery system of the present invention retain their activity and function, even though they are coupled by a stable, incleavable covalent link.
[0011] According to one aspect, a nanodelivery system is provided, comprising: inorganic nanoparticles bound to a first linear polymeric linker and a second linear polymeric linker, wherein the first and second linear polymeric linkers have significantly different lengths; a brain-mediated transporter component coupled to the first linear polymeric linker; and an active pharmaceutical agent selected from bioactive molecules or labeled molecules, wherein the pharmaceutical agent is coupled to the second linear polymeric linker.
[0012] According to some embodiments, the first and second polymeric connectives are indivisible under physiological conditions.
[0013] According to some embodiments, the molecular weights of the first and second linear polymeric linkers differ by at least about 1400 Da. According to other embodiments, the molecular weights of the first and second linear polymeric linkers are in the range of 1,000-10,000 Da. In some embodiments, the molecular weight of the first linear polymeric linker is higher than that of the second linear polymeric linker.
[0014] According to some embodiments, the first linear polymeric linker is composed of repeating monomer units, and the second linear polymeric linker is composed of the same repeating monomer units as the first linear polymeric linker, and the first linear polymeric linker has a different number of repeating monomer units than the second linear polymeric linker.
[0015] According to some embodiments, the brain-mediated transporter component is covalently coupled to the linker via a first terminal functional group of the first linear polymeric linker, and the active pharmaceutical agent is covalently coupled to the linker via a second terminal functional group of the second linear polymeric linker. In other embodiments, the first and second terminal functional groups are identical.
[0016] According to some embodiments, the inorganic nanoparticles are bound to the second linear polymeric linker via sulfur bonds, and the active agent is coupled to the second linear polymeric linker via amide bonds.
[0017] According to some embodiments, the first linear polymeric linker accounts for about 5% mol to 60% mol of the total polymeric linker bound to the inorganic nanoparticles.
[0018] According to some embodiments, the active pharmaceutical agent is a bioactive molecule. The active pharmaceutical agent may be selected from macromolecules, peptides, small molecules, oligonucleotides, antisense RNA, and any combination thereof. In some embodiments, the macromolecule is an antibody. In other embodiments, the first linear polymeric linker accounts for about 10% mol to 40% mol of the total polymeric linker bound to the inorganic nanoparticles.
[0019] According to some embodiments, the second linear polymeric linker accounts for about 5% mol to 60% mol of the total polymeric linker bound to the inorganic nanoparticles.
[0020] According to some embodiments, the first and second linear polymeric linkers independently comprise polymers selected from: polyethers, polyacrylates, polyanhydrides, polyvinyl alcohol, polysaccharides, poly(N-vinylpyrrolidone), polyglycerol (PG), poly(N-(2-hydroxypropyl)methacrylamide), polyoxazolines, poly(amino acid)-based hybrids, recombinant peptides, derivatives thereof, and combinations thereof. According to some embodiments, at least one of the first and second linear polymeric linkers is a polyether. In some exemplary embodiments, the polyether is polyethylene glycol (PEG). The polyethylene glycol may be selected from thiolized PEGylated acids (HS-PEG-COOH) and thiolized PEGylated amines (HS-PEG-NH2), wherein the thiolized ends are bound to the inorganic nanoparticles and the acid or amine ends are coupled to the brain-mediated transporter components or the active pharmaceutical ingredient.
[0021] According to some embodiments, the nanodelivery system further comprises a third polymeric linker bound to the inorganic nanoparticles, wherein the third polymeric linker is monofunctional. According to some embodiments, the third polymeric linker comprises a polymer selected from: polyethers, polyacrylates, polyanhydrides, polyvinyl alcohol, polysaccharides, poly(N-vinylpyrrolidone), polyglycerol (PG), poly(N-(2-hydroxypropyl)methacrylamide), polyoxazoline, poly(amino acid)-based hybrids, recombinant peptides, derivatives thereof, and combinations thereof. In some exemplary embodiments, the third polymeric linker comprises a polyether, wherein the polyether is methoxy polyethylene glycol (mPEG).
[0022] According to some embodiments, the inorganic nanoparticles are selected from metal nanoparticles, metal oxide nanoparticles, ceramic nanoparticles, and any combination thereof. The metal may be selected from gold, silver, platinum, iron, and any combination thereof. The metal oxide may be selected from iron oxide, magnesium oxide, nickel oxide, cobalt oxide, aluminum oxide, zinc oxide, copper oxide, manganese oxide, and any combination thereof. In some exemplary embodiments, the inorganic nanoparticles are selected from gold, iron(III) oxide, and iron(II,III) oxide. According to some embodiments, the inorganic nanoparticles have a diameter of 10-160 nm.
[0023] According to some embodiments, the brain-internalized transporter component is selected from: insulin, an antibody specifically targeting the insulin receptor, transferrin, an antibody specifically targeting the transferrin receptor, a polypeptide specifically binding to the transferrin receptor, a polypeptide specifically binding to the insulin receptor, insulin-like growth factor 1, an antibody specifically targeting insulin-like growth factor receptor 1, a polypeptide specifically binding to insulin-like growth factor receptor 1, apolipoprotein A1, B, or E, lactoferrin, angiopep-2, low-density lipoprotein, an antibody specifically targeting the low-density lipoprotein receptor or lipoprotein receptor-associated protein, a polypeptide specifically binding to the low-density lipoprotein receptor or lipoprotein receptor-associated protein, an antibody specifically targeting the diphtheria toxin receptor, a polypeptide specifically binding to the diphtheria toxin receptor, BBB-penetrating cell-penetrating peptide (CPP), and any combination thereof. In some embodiments, the brain-internalized transporter component is insulin.
[0024] According to certain exemplary embodiments, the inorganic nanoparticles are gold nanoparticles, the first linear polymeric linker is a thiolized PEG5000 acid or a thiolized PEG5000 amine, the second linear polymeric linker is a thiolized PEG3500 acid or a thiolized PEG3500 amine, and the brain-mediated transporter component is insulin.
[0025] According to certain exemplary embodiments, the inorganic nanoparticles are iron oxide nanoparticles, the first linear polymeric linker is a thiolized PEG5000 acid or a thiolized PEG5000 amine, the second linear polymeric linker is a thiolized PEG3500 acid or a thiolized PEG3500 amine, and the brain-mediated transporter component is insulin.
[0026] According to certain exemplary embodiments, the inorganic nanoparticles are gold nanoparticles, the first linear polymeric linker is a thiolized PEG1000 acid or a thiolized PEG1000 amine, the second linear polymeric linker is a thiolized PEG5000 acid or a thiolized PEG5000 amine, and the brain-mediated transporter component is insulin.
[0027] According to certain exemplary embodiments, the inorganic nanoparticles are gold nanoparticles, the first linear polymeric linker is a thiolized PEG5000 acid or a thiolized PEG5000 amine, the second linear polymeric linker is a thiolized PEG3500 acid or a thiolized PEG3500 amine, and the brain-mediated transporter component is transferrin.
[0028] On the other hand, a method for preparing a nanodelivery system according to various embodiments described above is provided, the method comprising the following sequential steps: (a) partially coating the surface of the inorganic nanoparticles with a first linear polymeric linker, and then coupling the first linear polymeric linker to the brain-mediated transporter component; and (b) partially coating the surface of the inorganic nanoparticles with a second linear polymeric linker, and then coupling the second linear polymeric linker to the active pharmaceutical agent, wherein steps (a) and (b) may be performed in any order.
[0029] According to some embodiments, the first polymeric linker has a first terminal functional group configured to bind the brain-mediated transporter component, and the second polymeric linker has a second terminal functional group configured to bind the active agent, wherein the first and second functional groups are identical.
[0030] According to some embodiments, the method further includes coating the surface of the inorganic nanoparticles with a third polymeric linker, wherein the polymeric linker is a single-function linker.
[0031] According to some embodiments, the active pharmaceutical agent is an antibody or peptide, and step (a) is performed prior to step (b).
[0032] According to some embodiments, the active pharmaceutical agent is a small molecule, and step (a) is performed after step (b).
[0033] According to some embodiments, each of the first linear polymeric linker and the second linear polymeric linker is added in an amount between 5% and 60% suitable for covering the surface of the inorganic nanoparticles.
[0034] In another aspect, a pharmaceutical composition is provided comprising a nanodelivery system and a pharmaceutically acceptable carrier according to various embodiments presented above.
[0035] According to some embodiments, the pharmaceutical composition is formulated for at least one of intravenous (IV), intranasal (IN), and intrathecal (IT) administration. According to some embodiments, the pharmaceutical composition is used for the prevention, treatment, and / or monitoring of brain-related diseases or disorders in subjects of need.
[0036] In another aspect, a method is provided for the prevention, treatment, and / or monitoring of brain-related diseases or disorders in subjects in need, the method comprising administering to the subject a pharmaceutical composition according to various embodiments described above.
[0037] According to certain embodiments, the pharmaceutical composition is administered to the subject by at least one of intravenous (IV), intranasal (IN), and intrathecal (IT) administration.
[0038] According to some embodiments, the method further includes the step of imaging the subject's brain to assess the accumulation of the nanodelivery system in the subject's brain. The imaging may be performed using an imaging system selected from: computed tomography (CT), X-ray imaging, magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT), ultrasound (US), and any combination thereof.
[0039] In another aspect, a nanodelivery system is provided, comprising: inorganic nanoparticles bound to a first linear polymeric linker and a second linear polymeric linker, wherein the first and second linear polymeric linkers have significantly different lengths; and a brain-mediated transporter component coupled to the first linear polymeric linker, wherein the second polymeric linker has free terminal functional groups configured for coupling to an active agent selected from bioactive molecules or labeled molecules.
[0040] According to some embodiments, the first and second polymeric connectives are indivisible under physiological conditions.
[0041] In some embodiments, the molecular weights of the first and second linear polymeric linkers differ by at least about 1000 Da. In some embodiments, the molecular weights of the first and second linear polymeric linkers differ by at least about 1400 Da. In other embodiments, the molecular weights of the first and second linear polymeric linkers are in the range of 1,000-10,000 Da. In some embodiments, the molecular weight of the first linear polymeric linker is higher than that of the second linear polymeric linker.
[0042] According to some embodiments, the first linear polymeric linker is composed of repeating monomer units, and the second linear polymeric linker is composed of the same repeating monomer units as the first linear polymeric linker, wherein the first linear polymeric linker has a different number of repeating monomer units than the second linear polymeric linker.
[0043] According to some embodiments, the brain-mediated transporter component is covalently coupled to the linker via a first terminal functional group of the first linear polymeric linker. According to some embodiments, the first terminal functional group of the first linear polymeric linker and the terminal functional group of the second linear polymeric linker configured for coupling the active pharmaceutical ingredient are the same.
[0044] According to some embodiments, the first linear polymeric linker accounts for about 5% mol to 60% mol of the total polymeric linker bound to the inorganic nanoparticles. In other embodiments, the first linear polymeric linker accounts for about 10% mol to 40% mol of the total polymeric linker bound to the inorganic nanoparticles. According to some embodiments, the second linear polymeric linker accounts for about 5% mol to 60% mol of the total polymeric linker bound to the inorganic nanoparticles.
[0045] According to some embodiments, the first and second linear polymeric linkers independently comprise polymers selected from: polyethers, polyacrylates, polyanhydrides, polyvinyl alcohol, polysaccharides, poly(N-vinylpyrrolidone), polyglycerol (PG), poly(N-(2-hydroxypropyl)methacrylamide), polyoxazolines, poly(amino acid)-based hybrids, recombinant peptides, derivatives thereof, and combinations thereof. According to some embodiments, at least one of the first and second linear polymeric linkers is a polyether. In some embodiments, the polyether is polyethylene glycol (PEG). The polyethylene glycol may be selected from thiolated PEG acids (HS-PEG-COOH) and thiolated PEG amines (HS-PEG-NH2), wherein the thiolated terminus is bound to the inorganic nanoparticles, and the acid or amine terminus is coupled to the brain-mediated transport protein component or configured to couple to the active pharmaceutical ingredient.
[0046] According to some embodiments, the nanodelivery system includes a third polymeric linker bound to the inorganic nanoparticles, wherein the third polymeric linker is single-functional. According to some embodiments, the third polymeric linker includes polymers selected from: polyethers, polyacrylates, polyanhydrides, polyvinyl alcohol, polysaccharides, poly(N-vinylpyrrolidone), polyglycerol (PG), poly(N-(2-hydroxypropyl)methacrylamide), polyoxazoline, poly(amino acid)-based hybrids, recombinant peptides, derivatives thereof, and combinations thereof. In some exemplary embodiments, the third polymeric linker includes a polyether, wherein the polyether is methoxy polyethylene glycol (mPEG).
[0047] According to some embodiments, the inorganic nanoparticles are selected from metal nanoparticles, metal oxide nanoparticles, ceramic nanoparticles, and any combination thereof. The metal may be selected from gold, silver, platinum, iron, and any combination thereof. The metal oxide may be selected from iron oxide, magnesium oxide, nickel oxide, cobalt oxide, aluminum oxide, zinc oxide, copper oxide, manganese oxide, and any combination thereof. In some embodiments, the inorganic nanoparticles are selected from gold, iron(III) oxide, and iron(II,III) oxide. According to some embodiments, the inorganic nanoparticles have a diameter of 10-160 nm.
[0048] According to some embodiments, the brain-internalized transporter component is selected from: insulin, an antibody specifically targeting the insulin receptor, transferrin, an antibody specifically targeting the transferrin receptor, a polypeptide specifically binding to the transferrin receptor, a polypeptide specifically binding to the insulin receptor, insulin-like growth factor 1, an antibody specifically targeting insulin-like growth factor receptor 1, a polypeptide specifically binding to insulin-like growth factor receptor 1, apolipoprotein A1, B, or E, lactoferrin, angiopep-2, low-density lipoprotein, an antibody specifically targeting the low-density lipoprotein receptor or lipoprotein receptor-associated protein, a polypeptide specifically binding to the low-density lipoprotein receptor or lipoprotein receptor-associated protein, an antibody specifically targeting the diphtheria toxin receptor, a polypeptide specifically binding to the diphtheria toxin receptor, BBB-penetrating cell-penetrating peptide (CPP), and any combination thereof. In some embodiments, the brain-internalized transporter component is insulin.
[0049] Other embodiments and the full scope of the invention will become apparent from the detailed description given below. However, it should be understood that while the detailed description and specific examples indicate preferred embodiments of the invention, they are given merely as illustrations, as various changes and modifications within the spirit and scope of the invention will be apparent to those skilled in the art from this detailed description. Attached Figure Description
[0050] Figure 1 : Schematic diagram of gold nanoparticles (GNP; 1) which incorporate: i) a first linear polymeric linker (2) coupled to insulin (3); ii) a shorter second linear polymeric linker (4) coupled to a bioactive molecule (e.g., antibody; 5); and iii) a polymeric component (6) with inert terminal groups.
[0051] Figure 2 UV-Vis spectra of EGFR & Ins-GNPs after various synthetic steps: before coating (GNPs); after coating with PEGs (~5kDa) and insulin (GNPs+PEGs+Ins); after coating with additional PEG linkers (~3.5kDa; GNPs+PEGs+Ins+PEG); and finally after coupling with EGFR Ab (GNPs+PEGs+Ins+PEG+Ab).
[0052] Figure 3 SDS-PAGE of free insulin (free INS), free EGFR Ab (free Ab), GNP, PEG-coated GNP (GNP+PEG), insulin-coated GNP (GNP+PEG+INS), and EGFR+Ins-GNP (GNP+PEG+INS+Ab).
[0053] Figures 4A-4C Representative miniature CT 3D volumetric rendering images of mouse brains 5 hours after the following treatment: intravenous (IV) administration of 200 μl mPEG-GNPs (control); Figure 4A ); Intravenous (IV) administration of 200 μl EGFR-Ins-GNPs Figure 4B ); and intranasal (IN) administration of 20 μl EGFR-Ins-GNPs ( Figure 4C ).
[0054] Figure 5A The amount of Au (mg) found in mouse brain tissue at different time points after intravenous administration of EGFR & Ins-GNPs was quantified by ICP-MS analysis.
[0055] Figure 5B The amount of Au (mg) found in the kidneys and livers of mice at different time points after intravenous administration of EGFR & Ins-GNPs was quantified by ICP-MS analysis.
[0056] Figure 6A The amount of Au found in mouse brain tissue 8 hours after intravenous administration of IgG1 & Ins-GNPs or free fluorescent IgG1 antibody was quantified by ICP-MS analysis (mg Au / gr tissue).
[0057] Figure 6B Representative confocal immunocytochemical fluorescence images of brain slices from mice treated with IgG1 & Ins-GNPs (right panel) or free fluorescent antibodies (left panel).
[0058] Figures 7A-7B : Using Anti-Iba1 & Ins-GNPs ( Figure 7A ) or free fluorescent anti-Iba1 ( Figure 7B Representative super-resolution microscopic images of frontal lobe brain slices from mice treated with the drug.
[0059] Figure 8 UV-Vis spectra of uncoated (naked GNPs), PEG-coated GNPs, and the final PEP&Ins-GNPs.
[0060] Figures 9A-9B Representative miniature CT images of mouse brains 6 hours after intravenous (IV) administration of PEP&Ins-GNPs. Figure 9A WT mice; Figure 9B : 5XFAD mice.
[0061] Figure 9CThe amount of Au found in the brain tissue of WT mice (control) and 5XFAD mice (Alzheimer's disease) 6 hours after intravenous administration of PEP&Ins-GNPs was quantified by ICP-MS analysis (mg Au / gr tissue).
[0062] Figure 9D : Fluorescence microscopy images (x20 magnification; scale bar = 100 μm) of hippocampal coronal sections from control mice (WT; top image) or 5xFAD mice (Alzheimer's disease model mice; bottom image) after incubation with fluorescently labeled PEP & Ins-GNPs for 20 hours. Images from left to right: nuclear localization (DAPI staining); Aβ plaque localization (6E10 staining); PEP & Ins-GNP localization; and combined fluorescence images.
[0063] Figure 10A The amount of Au found in mouse brain tissue 8 hours after intravenous administration of cisplatin + insulin-GNPs or free cisplatin was quantified by ICP-MS analysis (mg Au / gr tissue).
[0064] Figure 10B The amount of Pt found in mouse brain tissue 8 hours after intravenous administration of cisplatin + insulin-GNPs or free cisplatin was quantified by ICP-MS analysis (mg Pt / gr tissue).
[0065] Figure 11 The transendothelial resistance (TEER) of BMEC-like cells (iBMECs) decreased after 2 hours of incubation with mPEG-GNPs (control particles), IgG1&Trf-GNPs or IgG1&Ins-GNPs.
[0066] Figure 12A : Quantification (mg / gr tissue) of the amount of Au found in the brain of mice 8 hours after intravenous administration of IgG1 & Ins-GNPs with different insulin levels ranging from 5% to 50%.
[0067] Figure 12B : Quantification (mg / gr tissue) of the amount of Au found in the brain of mice 8 hours after intravenous administration of IgG1 & Ins-GNPs with different IgG1 Ab levels ranging from 20% to 85%.
[0068] Figure 12C : Quantification of the amount of Au (mg / gr tissue) found in the mouse brain 8 hours after intravenous administration of IgG1 & Ins-GNPs prepared using PEG-linked polymers of different sizes. Detailed Implementation
[0069] This invention provides a universal nanodelivery system for delivering different types of molecules with low BBB penetration into the brain, and a method for preparing said system. The delivery system is based on a core nanoparticle coupled to an internalized transporter component via a first polymeric linker and further coupled to a second polymeric linker capable of binding therapeutic or diagnostic agents. Without wishing to be limited by any theory or mechanism, it is assumed that the internalized transporter component facilitates the entire coupled system's entry into the brain across the BBB. Therefore, the delivery system of this invention can be used to treat and / or diagnose a wide range of brain-related diseases or disorders. This invention also provides pharmaceutical compositions and methods for therapeutic and / or diagnostic purposes.
[0070] This invention is partly based on the surprising discovery that nanoparticles coupled to brain-internalized transporter components (e.g., insulin) and bioactive molecules can overcome the blood-brain barrier's limiting mechanisms and provide a nanodelivery system for targeted delivery of diagnostic and / or therapeutic agents into the brain without releasing the agents from the delivery system after BBB penetration. As a diagnostic method, in some embodiments, this approach enables early detection of neurodegenerative diseases. As a therapeutic method, in some embodiments, this approach enables the delivery of targeted therapeutic agents.
[0071] Nanodelivery systems
[0072] According to one aspect, a nanodelivery system is provided, comprising:
[0073] (a) Nanoparticles, which are combined with a first linear polymeric linker and a second linear polymeric linker, wherein the first and second linear polymeric linkers have significantly different lengths;
[0074] (b) a brain-mediated transporter component, which is coupled to the first linear polymeric linker; and
[0075] (c) An active pharmaceutical agent selected from bioactive molecules or labeled molecules, wherein the pharmaceutical agent is coupled to the second linear polymer linker.
[0076] According to another aspect, a nanodelivery system is provided, comprising: nanoparticles bound to a first polymeric linker and a second polymeric linker; and a brain-mediated transporter component coupled to the first polymeric linker, wherein the first and second polymeric linkers have significantly different lengths, and wherein the second polymeric linker has free terminal functional groups configured for coupling to an active agent selected from bioactive molecules or labeled molecules.
[0077] When used herein, the term "nanodelivery system," which can be used interchangeably with the terms "particle" or "core-shell particle," refers to a nanoparticle-based system capable of delivering an active agent selected from bioactive substances or labeled molecules (e.g., imaging agents) to a target region, namely the brain of a subject, or, in some embodiments, to a specific region within the subject's brain. According to the principles of the invention, the active agent is coupled to the outer surface of the core nanoparticle via a polymeric linker, rather than being loaded or encapsulated within the nanoparticle core.
[0078] In some embodiments, the present invention provides a particle comprising a core and a shell, wherein the core comprises nanoparticles and the shell comprises a polymer-bound bioactive molecule or labeling molecule and a polymer-bound brain-mediated transporter component. When used herein, the term "shell" refers to the outer portion of the particle having a different composition from the core. In some embodiments, the volume ratio (v / v) of the brain-mediated transporter component in the shell is 5% to 60%.
[0079] In this document, the terms "nanoparticle" and "core nanoparticle," used interchangeably, refer to particles with a diameter between 1 and 1000 nm that constitute the central portion of the delivery system. The core nanoparticle is coated with a polymer layer comprising at least two polymers: a first polymeric linker that binds to components of brain-mediated transport proteins, and a second polymeric linker having free terminal functional groups capable of binding bioactive or labeled molecules. In some embodiments, the second polymer binds to bioactive or labeled molecules. Therefore, the delivery system of the present invention can be considered as a core-shell particle, wherein the core is a nanoparticle and the outer shell comprises a polymeric linker containing its corresponding coupling molecules.
[0080] In some embodiments, the nanoparticles are selected from metal nanoparticles, metal oxide nanoparticles, metal carbide nanoparticles, lipid nanoparticles, carbon-based nanoparticles, ceramic nanoparticles, polymer nanoparticles, and liposomes. Each possibility represents an independent embodiment of the invention. In some embodiments, the nanoparticles are inorganic nanoparticles. In some embodiments, the inorganic nanoparticles are selected from metal nanoparticles, metal oxide nanoparticles, and ceramic nanoparticles. In some embodiments, the inorganic nanoparticles are selected from metal nanoparticles and metal oxide nanoparticles. In some embodiments, the inorganic nanoparticles are metal nanoparticles. In other embodiments, the inorganic nanoparticles are metal oxide nanoparticles. In a particular embodiment, the inorganic nanoparticles are selected from gold nanoparticles and iron oxide nanoparticles.
[0081] In some embodiments, the metallic nanoparticles are magnetic nanoparticles. In some embodiments, the inorganic nanoparticles are magnetic nanoparticles. In some embodiments, the magnetic nanoparticles are contrast agents for magnetic resonance imaging (MRI). Any magnetic nanoparticles suitable for use as MRI contrast agents can be used in the compositions and methods of the present invention. The magnetic particles can be formed at least partially from any material affected by a magnetic field. Examples of suitable materials include, but are not limited to, magnetite, hematite, ferrite, and materials comprising one or more or combinations of iron, cobalt, manganese, nickel, chromium, gadolinium, neodymium, dysprosium, samarium, erbium, iron carbide, and iron.
[0082] In some embodiments, the inorganic nanoparticles are contrast agents for computed tomography (CT) or X-ray imaging. In some embodiments, the inorganic nanoparticles are metallic nanoparticles that can be used as contrast agents for CT or X-ray imaging. As will be apparent to those skilled in the art, in embodiments relating to diagnostic uses, any metal and / or combination of metals suitable for CT or X-ray imaging can be used in the metallic nanoparticles of the present invention. In some embodiments, the metals that can be used to form the nanoparticles of the present invention are heavy metals or metals with high Z values. Examples of suitable metals include, but are not limited to, gold, silver, platinum, palladium, cobalt, iron, copper, tin, tantalum, vanadium, molybdenum, tungsten, osmium, iridium, rhenium, hafnium, thallium, lead, bismuth, gadolinium, dysprosium, holmium, and uranium, or combinations thereof.
[0083] According to some embodiments, the inorganic nanoparticles are metal nanoparticles selected from gold nanoparticles, silver nanoparticles, platinum nanoparticles, iron nanoparticles, copper nanoparticles, and mixtures or combinations thereof. Each possibility represents an independent embodiment. In some embodiments, the metal nanoparticles are gold (Au) nanoparticles.
[0084] In some embodiments, the inorganic nanoparticles are metal oxide nanoparticles. In some embodiments, the metal oxide nanoparticles are selected from iron oxide (Fe₂O₃ or Fe₃O₄), magnesium oxide, nickel oxide, cobalt oxide, aluminum oxide, zinc oxide, copper oxide, and manganese oxide, or any combination thereof. Each possibility represents an independent embodiment of the invention. In some embodiments, the metal oxide nanoparticles comprise iron oxide selected from iron(III) and iron(II,III) oxides. In some embodiments, the metal oxide nanoparticles are iron oxide nanoparticles, wherein the iron oxide is selected from iron(III) and iron(II,III) oxides.
[0085] In some embodiments, the nanoparticles are selected from lipid nanoparticles, carbon-based nanoparticles, ceramic nanoparticles, polymer nanoparticles, and liposomes.
[0086] In some embodiments, the present invention provides a plurality of particles.
[0087] According to some embodiments, the particle delivery system has wavelengths of 5-500 nm, 6-400 nm, 8-300 nm, 10-300 nm, 10-200 nm, 10-180 nm, 10-160 nm, 10-150 nm, 10-100 nm, 20-90 nm, 20-80 nm, 20-70 nm, 20-60 nm, 25-100 nm, 25-90 nm, 25-80 nm, 25-70 nm, 25-60 nm, 25-50 nm, and 30 nm. Diameters of -60nm, 40-200nm, 40-150nm, 40-120nm, 40-100nm, 40-80nm, 40-60nm, 50-300nm, 50-250nm, 50-200nm, 50-180nm, 50-150nm, 60-200nm, 70-180nm, 80-180nm, 90-170nm, 100-160nm, 100-200nm, 150-200nm, or 150-180nm. According to some embodiments, the particle delivery system has a diameter of 2-200 nm, 1-100 nm, 1-150 nm, 1-200 nm, 2-50 nm, 2-100 nm, 2-150 nm, 4-50 nm, 4-100 nm, 4-150 nm, or 4-200 nm. Each possibility represents an independent embodiment. According to some embodiments, the particle has a diameter of at least 1 nm, at least 2 nm, at least 5 nm, at least 10 nm, at least 15 nm, at least 20 nm, at least 25 nm, at least 30 nm, at least 35 nm, at least 40 nm, at least 45 nm, at least 50 nm, at least 55 nm, at least 60 nm, at least 70 nm, at least 80 nm, at least 90 nm, at least 100 nm, at least 110 nm, at least 120 nm, at least 130 nm, at least 140 nm, at least 150 nm, at least 160 nm, at least 180 nm, or at least 200 nm. Each possibility represents an independent embodiment. According to certain embodiments, the particles have a diameter of up to 5 nm, up to 20 nm, up to 30 nm, up to 40 nm, up to 50 nm, up to 60 nm, up to 70 nm, up to 80 nm, up to 90 nm, up to 100 nm, up to 110 nm, up to 120 nm, up to 130 nm, up to 140 nm, up to 150 nm, up to 180 nm, up to 200 nm, up to 250 nm, up to 300 nm, up to 350 nm, up to 400 nm, up to 450 nm, or up to 500 nm. Each possibility represents an independent embodiment.
[0088] According to certain embodiments, the core nanoparticles have wavelengths of 1-200nm, 1-180nm, 1-160nm, 1-140nm, 1-120nm, 1-100nm, 1-90nm, 1-80nm, 1-70nm, 1-60nm, 1-50nm, 1-40nm, 2-100nm, 2-60nm, 2-50nm, 2-40nm, 2-30nm, 2-20nm, 2-10nm, 3-100nm, 3-60nm, 3-50nm, 3-40nm, 3-30nm, 3-20nm, 4-100nm, 4-60nm, 4-50nm, 4-40nm, 5-200nm, 6-190nm, 7-180nm, 8-170nm, 10-160nm, and 20nm. -160nm, 10-150nm, 10-140nm, 10-120nm, 10-110nm, 10-100nm, 10-90nm, 10-80nm, 12-70nm, 14-60nm, 15-50nm, 15-40nm, 15-30nm, 20-30nm, 15-30nm, 20-90nm, 20-80 nm, 20-70nm, 20-60m, 20-50nm, 20-40nm, 20-30nm, 30-70nm, 30-60nm, 40-60nm, 10 -200nm, 20-200nm, 30-200nm, 40-200nm, 50-200nm, 60-200nm, 70-200nm, 80-200nm Diameters of 90-200nm, 100-200nm, 110-190nm, 120-170nm, 130-160nm, 100-160nm, 80-160nm, 60-160nm, 40-160nm, 20-160nm, 10-160nm, 20-150nm, or 30-150nm. Each possibility represents an independent implementation. According to certain embodiments, the nanoparticles have a diameter of at least 1 nm, at least 2 nm, at least 3 nm, at least 4 nm, at least 5 nm, at least 10 nm, at least 12 nm, at least 15 nm, at least 18 nm, at least 20 nm, at least 25 nm, at least 30 nm, at least 35 nm, at least 40 nm, at least 45 nm, at least 50 nm, at least 60 nm, at least 70 nm, at least 80 nm, at least 90 nm, at least 100 nm, at least 110 nm, at least 120 nm, at least 130 nm, at least 140 nm, or at least 150 nm. Each possibility represents an independent embodiment.According to some embodiments, the nanoparticles have a diameter of up to 5 nm, up to 10 nm, up to 15 nm, up to 20 nm, up to 30 nm, up to 40 nm, up to 50 nm, up to 60 nm, up to 70 nm, up to 80 nm, up to 90 nm, up to 100 nm, up to 120 nm, up to 140 nm, up to 160 nm, up to 180 nm, or up to 200 nm. Each possibility represents an independent embodiment.
[0089] When used herein, the term "diameter" for a particle / nanoparticle is used interchangeably with the term "size" for a particle / nanoparticle and refers to the maximum straight-line distance between two points on the surface of the described particle / nanoparticle. When used herein, the term "diameter" encompasses the size of both spherical and non-spherical particles and can refer to the actual size of the particle or its hydrodynamic diameter, including contributions from the solvation range. The size of the particle can be determined using any method known in the art, such as transmission electron microscopy (TEM), scanning electron microscopy (SEM), and dynamic light scattering (DLS). The term "diameter" can also refer to the average diameter of multiple particles measured by any of the aforementioned techniques.
[0090] In some embodiments, the core nanoparticles are coated with a polymer layer comprising at least two polymer components bonded to the core nanoparticles. In some embodiments, the at least two polymer components are polymeric linkers.
[0091] When used herein, the term "coating" means that a layer, such as a polymer layer comprising multiple polymer components, is chemically attached to the surface of the core nanoparticle, thereby at least partially covering the core nanoparticle. "Nanoparticles coated with a polymer layer" means that each polymer component in the polymer layer is chemically attached to the nanoparticle via a terminal functional group, such as a thiol group, of the polymer component. This chemical attachment can be covalent, semi-covalent, or non-covalent.
[0092] The term "polymer component" is used interchangeably with the term "polymer" and refers to a molecule containing two or more repeating subunits linked in a linear, branched, superbranched, dendritic, or cyclic sequence or any combination thereof. In some embodiments, the term "polymer component" refers to a molecule containing at least three repeating subunits linked in a linear, branched, superbranched, dendritic, or cyclic sequence or any combination thereof. Examples of subunits include alkylene, arylene, heteroalkylene, amino acids, nucleic acids, sugars, etc. Examples of polymer components include, but are not limited to, poly(ethylene glycol) groups, poly(ethyleneamine) groups, and poly(amino acid) groups. The terms "polymer component" and "polymer" also encompass polymeric linkers. When used herein, the term "polymeric linker" refers to a polymer component that initially contains at least one functional group / reactive group capable of binding to a substance such as nanoparticles. In some embodiments, the polymeric linker is a bifunctional polymer having at least two functional groups / reactive groups capable of binding to at least two substances, thereby linking said at least two substances. In some embodiments, the polymeric linker is a monofunctional polymer having a functional group / reactive group capable of binding to a substance such as nanoparticles. It should be understood that, as used herein, the terms "monofunctional," "bifunctional," "functional group," etc., refer to polymeric linkers in their original form prior to attachment to said core nanoparticles and / or brain-mediated transporter components or active pharmaceutical agents.
[0093] In some embodiments, at least one of the first and second polymeric links is a linear polymeric linker. In some embodiments, the first polymeric linker is a linear polymeric linker. In some embodiments, the second polymeric linker is a linear polymeric linker. In some embodiments, the linear polymeric linker is a bifunctional linear polymer having two functional groups / reactive groups at its two ends. In some embodiments, both the first and second polymeric links are linear polymeric links. In some embodiments, both the first and second polymeric links are linear bifunctional polymeric links having two functional groups / reactive groups at their two ends.
[0094] When used herein, the term "linear" polymer / polymer linker refers in some embodiments to a polymer / polymer linker in which at least 80% of the monomer units are linked in a linear manner, i.e., in the form of a single-chain polymer. In other embodiments, the term "linear" polymer / polymer linker refers to a polymer / polymer linker in which at least 90% of the monomer units are linked in a linear manner. In still other embodiments, the term "linear" polymer / polymer linker refers to a polymer / polymer linker in which approximately 100% of the monomer units are linked in a linear manner. When used herein, the term "single-chain polymer" refers to a polymer chain comprising linked monomers in such a manner that the monomer units are linked to each other by two atoms (one atom on each monomer unit).
[0095] In some embodiments, the core nanoparticle is bound to a first polymer. In some embodiments, the core nanoparticle is bound to a second polymer. In some embodiments, the core nanoparticle is bound to both the first and second polymers. In some embodiments, the core nanoparticle is bound to a first, second, and third polymer. In some embodiments, the core nanoparticle is bound to a first polymeric linker. In some embodiments, the core nanoparticle is bound to a second polymeric linker. In some embodiments, the core nanoparticle is bound to both the first and second polymeric linkers. In some embodiments, the core nanoparticle is bound to a first linear polymeric linker. In some embodiments, the core nanoparticle is bound to a second linear polymeric linker. In some embodiments, the core nanoparticle is bound to both the first and second linear polymeric linkers. In some embodiments, the core nanoparticle is bound to the first and second polymeric linkers and an additional polymeric component, wherein the additional polymeric component is single-functional, i.e., initially having a single terminal functional group configured to couple the polymer to the core nanoparticle. In some embodiments, the additional polymer is a single-functional linker.
[0096] The term “bonding” is used interchangeably with the term “coupling.” In some embodiments, bonding is covalent coupling. The terms “covalent attachment,” “covalent linkage,” “covalent connection,” and “covalent bond” are used interchangeably herein and refer to the formation of a chemical bond characterized by the sharing of electron pairs between atoms. For example, a covalently attached agent coating refers to an agent coating that forms a chemical bond with a functionalized surface of a substrate, unlike an agent attached to a surface by other means such as adhesion or electrostatic interactions. It should be recognized that agents (e.g., polymers) covalently attached to surfaces can also be bonded by means other than covalent attachment.
[0097] In some embodiments, the polymer components and / or linkers are attached to the outer surface of the core nanoparticles via chemical attachment selected from covalent, semi-covalent, or non-covalent attachment. Each possibility represents an independent embodiment of the invention. In some embodiments, the polymer components and / or linkers are attached to the outer surface of the core nanoparticles via semi-covalent attachment. When used herein, the term "semi-covalent attachment" refers to a coordinate bond in which the shared electron pair forming the bond originates from the same atom. In this disclosure, semi-covalent attachment can occur between metal nanoparticles, such as gold nanoparticles, and thiol groups.
[0098] In some embodiments, the first polymeric linker comprises a polymer selected from the following: polyethers, polyacrylates, polyanhydrides, polyvinyl alcohol, polysaccharides, poly(N-vinylpyrrolidone), polyglycerol (PG), poly(N-(2-hydroxypropyl)methacrylamide), polyoxazoline, poly(amino acid)-based hybrids, recombinant peptides, derivatives thereof, and combinations thereof. Each possibility represents an independent embodiment of the invention.
[0099] When used herein, the term “derivative” refers to a compound whose core structure is the same as or very similar to that of the parent compound, but which has chemical or physical modifications, such as different or additional groups, such as, but not limited to, alkoxy, carboxyl, amino, methoxy, and thiol groups.
[0100] In some embodiments, the first polymeric linker comprises a polyether. In some embodiments, the first polymeric linker is a polyether. In some embodiments, the polyether is polyethylene glycol (PEG) or a derivative thereof.
[0101] Where appropriate, the abbreviation (PEG) is used in combination with a numerical suffix indicating the average molecular weight of the PEG. One form of PEG or PEG-like substances is PEG or PEG derivatives having a specified average molecular weight.
[0102] When used herein, "PEG or a derivative thereof" refers to any compound comprising at least one polyethylene glycol component. PEG exists in a linear form and in a branched form comprising multiple arms and / or grafted polyethylene glycols. When used herein, the term "PEG derivative" refers to PEG modified by alkylation of terminal hydroxyl groups. In some embodiments, the terminal hydroxyl groups are alkylated with straight-chain or branched C1-C6 alkyl groups. PEG may also contain functional groups. PEG can be a monofunctional, bifunctional, or multifunctional polyethylene glycol.
[0103] Exemplary functional groups include, but are not limited to, hydroxyl, carboxyl, thiol, amine, phosphate ester, phosphonate, sulfate ester, sulfite ester, sulfonate, sulfoxide, sulfone, amide, ester, ketone, aldehyde, cyano, alkyne, azide and olefin or combinations thereof.
[0104] In some embodiments, the brain-mediated transporter component is covalently coupled to the linker via a first terminal functional group of the first polymeric linker, and the active pharmaceutical agent is covalently coupled to the linker via a second terminal functional group of the second polymeric linker. In some embodiments, the first and second terminal functional groups are the same. In other embodiments, the first and second terminal functional groups are different.
[0105] In some embodiments, the first polymeric linker comprises a thiol (-SH) terminal group. In some embodiments, the first polymeric linker is chemically attached to the nanoparticles via the thiol (-SH) terminal group. In some embodiments, the first polymeric linker is coupled to the endogenous transporter component via an amide bond. In some embodiments, the nanoparticles are bound to the first polymeric linker via sulfur bonds, and the endogenous transporter component is coupled to the first polymeric linker via an amide bond. In some embodiments, the first polymeric linker in the nanodelivery system has the structure -SR-CONH-, where R is a polymer chain composed of repeating monomer units. In other embodiments, the first polymeric linker in the nanodelivery system has the structure -SR-NHCO-, where R is a polymer chain composed of repeating monomer units. In some embodiments, the first polymeric linker is selected from thiolized PEGylic acid (HS-PEG-COOH) and thiolized PEGamine (HS-PEG-NH2). It should be understood that the HS and COOH / NH2 terminal groups refer to the polymeric linker prior to coupling with the nanoparticles and the endogenous transporter component. In some embodiments, the thiol group is chemically attached to the core nanoparticle, and the acid or amine group is covalently coupled to the brain-mediated transporter component. In some embodiments, the first polymeric linker in the nanodelivery system has a structure selected from -S-PEG-C(O)- and -S-PEG-NH-.
[0106] In some embodiments, the first polymeric connector is an indivisible connector. In some embodiments, the first polymeric connector is indivisible under physiological conditions.
[0107] When used herein, the term "uncleavable" refers to stable bonds that are insensitive to acids or bases, to reducing or oxidizing agents, and to enzymes that can be found in cells or the circulatory system. In some embodiments, the first and / or second polymeric linkers are free of pH-sensitive hydrazones. In some embodiments, the first and / or second polymeric linkers are free of disulfide bonds. In some embodiments, the first and / or second polymeric linkers are free of ester bonds. It should be understood that the term "polymeric linker is uncleavable" is intended to cover the bonds between the nanoparticles and the polymeric linker, the bonds between the corresponding polymeric linker and the active pharmaceutical ingredient, and the bonds between the corresponding polymeric linker and brain-mediated transporter components, as well as any bonds within the polymeric linker itself.
[0108] In some embodiments, the first polymeric linker has a concentration selected from 500-10,000 Da, 600-9,500 Da, 700-9,000 Da, 800-8,500 Da, 800-6,000 Da, 800-5,000 Da, 800-4,000 Da, 800-3,000 Da, 800-2,000 Da, 900-8,000 Da, 1,000-7,000 Da, 1,500-6,500 Da, 2,000-6,000 Da, and 3,000-6,000 Da. Molecular weights (MW) in the ranges of 4,000-6,000 Da, 3,400-7,000 Da, 2,000-3,000 Da, 2,000-5,000 Da, 2,000-7,000 Da, 2,000-10,000 Da, 3,000-3,400 Da, 3,000-5,000 Da, 3,000-7,000 Da, 3,000-10,000 Da, 5,000-7,000 Da, 5,000-10,000 Da, and 7,000-10,000 Da. Each possibility represents an independent implementation. According to some embodiments, the first polymeric linker has a MW of at least 1,000 Da, at least 1,500 Da, at least 2,000 Da, at least 2,500 Da, at least 3,000 Da, at least 3,400 Da, at least 4,000 Da, at least 5,000 Da, at least 6,000 Da, at least 7,000 Da, or at least 8,000 Da. Each possibility represents an independent embodiment. According to some embodiments, the first polymeric linker has a MW of at most 3,000 Da, at most 4,000 Da, at most 5,000 Da, at most 6,000 Da, at most 7,000 Da, or at most 10,000 Da. Each possibility represents an independent embodiment.
[0109] In some embodiments, the second polymeric linker comprises a polymer selected from the following: polyethers, polyacrylates, polyanhydrides, polyvinyl alcohol, polysaccharides, poly(N-vinylpyrrolidone), polyglycerol (PG), poly(N-(2-hydroxypropyl)methacrylamide), polyoxazoline, (polyamino acid)-based hybrids, recombinant peptides, derivatives thereof, and combinations thereof. Each possibility represents an independent embodiment of the invention.
[0110] In some embodiments, the second polymeric linker comprises a polyether. In some embodiments, the second polymeric linker is a polyether. In some embodiments, the polyether is polyethylene glycol (PEG) or a derivative thereof.
[0111] In some embodiments, the second polymeric linker comprises a thiol (-SH) terminal group. In some embodiments, the second polymeric linker is chemically attached to the nanoparticles via the thiol (-SH) terminal group. In some embodiments, the second polymeric linker is coupled to the active pharmaceutical ingredient via an amide bond. In some embodiments, the nanoparticles are bonded to the second polymeric linker via sulfur bonds, and the active pharmaceutical ingredient is coupled to the second polymeric linker via an amide bond. In some embodiments, the second polymeric linker in the nanodelivery system has the structure -SR-CONH-, where R is a polymer chain composed of repeating monomer units. In other embodiments, the second polymeric linker in the nanodelivery system has the structure -SR-NHCO-, where R is a polymer chain composed of repeating monomer units. In some embodiments, the second polymeric linker is selected from thiolized PEGylic acids (HS-PEG-COOH) and thiolized PEGylated amines (HS-PEG-NH2). It should be understood that the HS and COOH / NH2 terminal groups refer to the polymeric linker prior to coupling with the nanoparticles and the active pharmaceutical ingredient. In some embodiments, the thiol group is chemically attached to the core nanoparticle, and the acid or amine group is covalently coupled to the active pharmaceutical ingredient. In some embodiments, the second polymeric linker in the nanodelivery system has a structure selected from -S-PEG-C(O)- and -S-PEG-NH-.
[0112] In some embodiments, the second polymeric connector is an indivisible connector. In some embodiments, the second polymeric connector is indivisible under physiological conditions.
[0113] In some embodiments, the second polymeric linker has a molecular weight (MW) between 2,000 and 7,000 Da. In some embodiments, the second polymeric linker has a molecular weight (MW) selected from 500-10,000 Da, 600-9,500 Da, 700-9,000 Da, 800-8,500 Da, 800-6,000 Da, 800-5,000 Da, 800-4,000 Da, 800-3,000 Da, 800-2,000 Da, 900-8,000 Da, 1,000-7,000 Da, 1,500-6,500 Da, 2,000-6,000 Da, 3,000-6,000 Da, 4,000-6,000 Da, 1,000-7,000 Da, 1,500-6,500 Da, 2,000-6,000 Da, 3,000-6,000 Da, 4,000-6,000 Da, 1,000-7,000 Da. The MW values are within the ranges of 0-2,000Da, 1,000-3,000Da, 1,000-5,000Da, 1,000-7,000Da, 1,000-10,000Da, 2,000-3,000Da, 2,000-5,000Da, 2,000-7,000Da, 2,000-10,000Da, 3,000-5,000Da, 3,000-7,000Da, 3,000-10,000Da, 5,000-7,000Da, 5,000-10,000Da, and 7,000-10,000Da. Each possibility represents an independent implementation. According to some embodiments, the second polymeric linker has a MW of at least 1,000 Da, at least 2,000 Da, at least 3,000 Da, at least 4,000 Da, at least 5,000 Da, at least 6,000 Da, or at least 7,000 Da. Each possibility represents an independent embodiment. According to some embodiments, the second polymeric linker has a MW of at most 2,000 Da, at most 3,000 Da, at most 4,000 Da, at most 5,000 Da, at most 6,000 Da, at most 7,000 Da, or at most 10,000 Da. Each possibility represents an independent embodiment.
[0114] In some embodiments, the nanodelivery system comprises a polymer-bound bioactive molecule, wherein the polymer comprises a cleavable linker. According to some embodiments, the cleavable linker comprises a bond sensitive to cleavage of endogenous molecules located in or expressed in the brain. In some embodiments, the cleavable linker is PEG-succinimide succinate (PEGSS). According to some embodiments, the endogenous molecule is glutathione. According to some embodiments, the endogenous molecule is selected from proteases, nucleases, hydrated hydrogen ions, and reducing agents. Each possibility represents an independent embodiment.
[0115] According to some embodiments, the nanodelivery system further comprises a cleavage molecule inducer. According to some embodiments, the cleavage molecule inducer is selected from N-acetyl-1-cysteine (NAC), glutathione monoester, γ-glutamylcysteine, γ-glutamylcysteine synthase, and glutathione synthase. Each possibility represents an independent embodiment.
[0116] In some embodiments, the endogenous molecule is glutathione, and the cleavage molecule inducer is selected from N-acetyl-1-cysteine (NAC), glutathione monoester, γ-glutamylcysteine, γ-glutamylcysteine synthase, and glutathione synthase.
[0117] According to some embodiments, the first polymer and the second polymer are different polymers. In some embodiments, the first polymer and the second polymer comprise the same polymer. In other embodiments, the first polymeric linker consists of repeating monomer units, and the second polymeric linker consists of the same repeating monomer units as the first linear polymeric linker. In some related embodiments, the first linear polymeric linker has a different number of repeating monomer units than the second linear polymeric linker.
[0118] In some embodiments, the first and second polymeric linkers comprise the same polymer selected from: polyethers, polyacrylates, polyanhydrides, polyvinyl alcohol, polysaccharides, poly(N-vinylpyrrolidone), polyglycerol (PG), poly(N-(2-hydroxypropyl)methacrylamide), polyoxazoline, poly(amino acid)-based hybrids, recombinant peptides, derivatives thereof, and combinations thereof. In some embodiments, both the first and second polymeric linkers comprise PEG. In some embodiments, both the first and second polymeric linkers are PEG. In some embodiments, both the first and second polymeric linkers comprise thiolated PEG. In some embodiments, the first and second polymeric linkers comprise thiolated PEGylic acid (HS-PEG-COOH) or thiolated PEGamine (HS-PEG-NH2). In some embodiments, the first and second polymeric linkers are thiolated PEGylic acid (HS-PEG-COOH) or thiolated PEGamine (HS-PEG-NH2). In some embodiments, both the first and second polymeric linkers are thiolated PEGylic acid (HS-PEG-COOH). In some embodiments, both the first and second polymeric linkers are thiolized PEG-amines (HS-PEG-NH2).
[0119] In some embodiments, the first and second polymeric connectors are linear. According to the principles of the invention, the first and second linear polymeric connectors have significantly different lengths.
[0120] In some embodiments, the term “length” of a polymer component or linker refers to the length of the polymer, which depends on the number of monomers incorporated therein, the length of each monomer unit, the structure of the polymer chain (e.g., whether the polymer is linear or branched), the spatial conformation, the deformation of the valence angle (or bonding angle), and the degree of stretching or curling.
[0121] The length of polymers can be calculated as is known in the art, for example, as described in Chapter 3 of *Introduction to Physical Polymer Science*, 4th Edition, LHSperling, first published: November 4, 2005. Furthermore, as is known in the art, various computational modeling methods, particularly those using Hyperchem, ACD / 3D, MOE 2010.10, or Chem3D software, can be used to assess the length of polymers. Physical characterization methods, such as static light scattering, can also be used to assess the length of coiled polymers. It should be understood that when assessing the difference in length between the first and second polymeric links, the same definition of length (or length measurement method) must be used for both polymeric links.
[0122] The term "length" when referring to linear polymers can refer to different definitions of length. According to some implementations, the term "length" refers to displacement length, also referred to herein as "end-to-end" length, which for coiled polymers is the distance between the two ends of the polymer chain. For example, end-to-end length can be expressed as the Flory radius:
[0123] Equation I: F = αn³ / 5
[0124] Where F = Flory radius, a = monomer size, and n = degree of polymerization.
[0125] According to some embodiments, the term "length" refers to the profile length, which is the distance between the two ends of the polymer chain when the polymer is stretched. The profile length can be considered as the maximum possible displacement length. The profile length (also referred to herein as the "old profile length") can be calculated by dividing the polymer's MW by the monomer unit's MW and multiplying by the length of the monomer unit. To take the bonding angle into account, the profile length (also referred to herein as the "new profile length") can be calculated by dividing the polymer's MW by the monomer unit's MW, multiplying by the length of the monomer unit, and then multiplying by the cosine of ((bonding angle θ - 180) / 2).
[0126] As explained above, the length of a linear polymer can be estimated based on its molecular weight and the chemical structure of its monomer units. To assess the difference in length between a first and a second linear polymer linker comprising the same polymer (i.e., composed of monomer units of the same type but different numbers), the molecular weights of the two polymer linkers can be conveniently used. Therefore, in some embodiments, the first and second linear polymer linkers have significantly different molecular weights. When used herein, the term "significantly different" means a difference of at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 12%, at least 15%, at least 18%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50%. Each possibility represents an independent embodiment of the invention.
[0127] In some embodiments, the monomer units of the first polymeric linker and the monomer units of the second polymeric linker have substantially similar molecular weights. When used herein, the term "substantially similar" means at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, or at least 95% similarity. Each possibility represents an independent embodiment of the invention.
[0128] In some embodiments, the first and second polymeric links comprise similar polymers. In some embodiments, the first linear polymeric link is composed of repeating monomer units, and the second linear polymeric link is composed of the same repeating monomer units as the first linear polymeric link, wherein the first linear polymeric link has a different number of repeating monomer units than the second linear polymeric link. In some embodiments, the first and second polymeric links are similar except for their lengths.
[0129] In some embodiments, the difference in molecular weight between the corresponding first and second linear polymeric linkers is at least about 100 Da, at least about 150 Da, at least about 200 Da, at least about 250 Da, at least about 300 Da, at least about 350 Da, at least about 400 Da, at least about 450 Da, at least about 500 Da, at least about 550 Da, at least about 600 Da, at least about 650 Da, at least about 700 Da, at least about 750 Da, at least about 800 Da, at least about 850 Da, at least about 900 Da, at least about 950 Da, at least about 1000 Da, at least about 1100 Da, at least about 1200 Da, at least about 1300 Da, at least about 1400 Da, or at least about 1500 Da. Each possibility represents an independent embodiment of the invention.
[0130] In some embodiments, the length difference between the first and second linear polymeric linkers is configured to expose the brain-derived transporter component on the BBB-facing outer surface of the nanodelivery system. It should be understood that the active agent is not enclosed within the nanoparticle core, but rather attached to its outer surface via polymeric linkers, similar to the brain-derived component, which is also attached to the surface of the same nanoparticle core via polymeric linkers. However, this core-shell structure, which can be formed by relatively simple preparation methods, encounters an unexpected obstacle—BBB penetration efficiency is very low when using polymeric linkers of the same type and molecular weight to couple the brain-derived component and the active agent. It is undesirable to be limited by theory or mechanism of action, as polymer chains of similar length do not provide sufficient exposure of the brain-derived component on the outer surface of the delivery system. To overcome this obstacle, polymeric linkers of different lengths are used to couple the brain-derived component and the active agent. The inventors of this invention have surprisingly discovered that a first polymeric linker with a higher molecular weight than a second polymeric linker (where both polymeric linkers are composed of the same monomeric units) allows for the delivery of active agents of varying structures and sizes, including antibodies, peptides, and small molecules, into the brain. Not wishing to be limited by theory or mechanism of action, it is envisioned that a linker with a higher molecular weight (MW) as the first polymeric linker has a larger profile distance and end-to-end distance than the second polymeric linker, thus enabling the exposure of the brain-internalized transporter components and / or shielding of the active agents, providing penetration into the BBB. Therefore, a nanodelivery system comprising a first polymeric linker with a length and / or MW greater than the second polymeric linker provides a universal BBB-penetrating platform for delivering a wide variety of bioactive molecules or labeled components.
[0131] Not wanting to be limited by theories or mechanisms of action, the active pharmaceutical agent, not encapsulated or sealed within a nanoparticle core, is envisioned as being available and active despite being bound to the delivery system. It has been unexpectedly found that antibodies conjugated to polymeric linkers bound to the nanoparticles via stable, incleavable covalent bonds retain their activity and function. Even more surprisingly, peptides targeting amyloid-β plaques conjugated to polymeric linkers bound to the nanoparticles retain their targeting ability in the brain, despite being at least partially shielded by insulin conjugated to polymeric linkers longer than the peptides. Therefore, the nanodelivery system of the present invention ensures the formation of specific compositions of conjugated particles with specific hierarchical structures, allowing not only the delivery of various types of active pharmaceutical agents but also, without interfering with the function of the active pharmaceutical agents, making it unnecessary to cleave the link between the active pharmaceutical agent and the nanoparticles after crossing the BBB.
[0132] Therefore, in some embodiments, the molecular weight of the first polymeric linker is higher than the molecular weight of the second polymeric linker. In some embodiments, the molecular weight of the first polymeric linker is higher than the molecular weight of the second polymeric linker, provided that the molecular weight of the second polymeric linker is less than 4950 Da. In some embodiments, the molecular weight of the first polymeric linker is higher than the molecular weight of the second polymeric linker, provided that the molecular weight of the second polymeric linker is less than 4900 Da. In some embodiments, the molecular weight of the first polymeric linker is higher than the molecular weight of the second polymeric linker, provided that the molecular weight of the second polymeric linker is less than 4800 Da. In some embodiments, the molecular weight of the first polymeric linker is higher than the molecular weight of the second polymeric linker, provided that the molecular weight of the second polymeric linker is less than 4780 Da. In some embodiments, the first polymeric linker is a PEG derivative with a molecular weight of approximately 5 kDa, and the second polymeric linker is a PEG derivative with a molecular weight of approximately 3500 kDa.
[0133] In some embodiments, the first polymeric linker has a higher molecular weight than the second polymeric linker. In some embodiments, the molecular weight (MW) of the first and second polymeric linkers is directly dependent on the relative molecular weights of the bioactive molecule and the brain-derived component. In some embodiments, the bioactive molecule has a higher molecular weight (Mw) than the brain-derived component, and the first polymeric linker has a higher MW than the second polymeric linker.
[0134] In some embodiments, the first polymeric connector is longer than the second polymeric connector. In some embodiments, the first polymeric connector has a longer end-to-end distance than the second polymeric connector. In some embodiments, the first polymeric connector has a longer profile distance than the second polymeric connector.
[0135] In some embodiments, the first polymeric linker has a smaller molecular weight (MW) than the second polymeric linker. In some related embodiments, the second polymeric linker has a MW of at least about 4000 Da, and the difference in MW between the first and second polymeric linkers is at least about 2000 Da. In other embodiments, the second polymeric linker has a MW of at least about 4500 Da, and the difference in MW between the first and second polymeric linkers is at least about 2500 Da. In other embodiments, the second polymeric linker has a MW of at least about 4700 Da, and the difference in MW between the first and second polymeric linkers is at least about 3000 Da. Not wanting to be limited by theory or mechanism of action, it is envisioned that a significantly longer second linker would allow for folding (or a greater degree of coiling) of the polymer chains, such that the actual distance between the bioactive molecule and the nanoparticle core is less than the actual distance between the endogenous component and the nanoparticle core, such that the bioactive molecule is at least partially shielded by the endogenous component exposed on the surface of the delivery system during BBB penetration. In some related embodiments, the end-to-end distance of the first polymeric connector is greater than the end-to-end distance of the second polymeric connector, even though the MW of the second polymeric connector is higher.
[0136] In some embodiments, the distance between the bioactive molecule and the nanoparticle core is smaller than the distance between the brain-derived component and the nanoparticle core. In some embodiments, at least one terminal group of the first polymeric linker is similar to at least one terminal group of the second polymeric linker. In some embodiments, at least one terminal functional group of the first polymeric linker is similar to at least one terminal functional group of the second polymeric linker. In some embodiments, two terminal groups of the first polymeric linker are similar to two terminal groups of the second polymeric linker. In some embodiments, two terminal functional groups of the first polymeric linker are similar to two terminal functional groups of the second polymeric linker.
[0137] In some embodiments, the nanoparticles are bound to an additional third polymer. In some embodiments, the polymer is a monofunctional polymeric linker. In some embodiments, the nanoparticles are coated with a polymer layer comprising the first polymeric linker, the second polymeric linker, and an additional third polymeric linker, wherein the additional polymeric linker is monofunctional. The terms "third polymer" and "third polymeric linker" are used interchangeably. In some embodiments, the third polymer functions as a spacer component. In some embodiments, the third polymeric linker is a linear polymeric linker. In some embodiments, the third polymer is selected from polyethers, polyacrylates, polyanhydrides, polyvinyl alcohol, polysaccharides, poly(N-vinylpyrrolidone), polyglycerol (PG), poly(N-(2-hydroxypropyl)methacrylamide), polyoxazoline, poly(amino acid)-based hybrids, recombinant peptides, derivatives thereof, and combinations thereof.
[0138] When used herein, the term "single-functional" means that the polymer has only one functional group configured to bind the polymer to the nanoparticles prior to being coupled to them. Therefore, the single-functional polymer linker neither couples to nor can couple to any other components besides the nanoparticles.
[0139] In some embodiments, the third polymer comprises the same monomer units as the first and / or second polymers. In some embodiments, the third polymer is bound to the nanoparticles via thiol-terminated groups. In some embodiments, the third polymer is a polyether. In some embodiments, the polyether is methoxy polyethylene glycol (mPEG) or a derivative thereof. In some embodiments, the mPEG is thiolated (mPEG-SH), wherein the thiolated mPEG is bound to the core nanoparticles via thiol-terminated groups.
[0140] In some embodiments, the third polymer has a molecular weight (MW) between 1,000 and 7,000 Da. In some embodiments, the third polymer has MWs of 500-1,000 Da, 500-3,000 Da, 500-7,000 Da, 500-10,000 Da, 1,000-3,000 Da, 1,000-5,000 Da, 1,000-7,000 Da, 1,000-10,000 Da, 3,000-5,000 Da, 3,000-7,000 Da, 3,000-10,000 Da, and 7,000-10,000 Da. Each possibility represents an independent implementation. According to some embodiments, the third polymer has a molecular weight (MW) of at least 1,000 Da, at least 2,000 Da, at least 3,000 Da, at least 4,000 Da, at least 5,000 Da, at least 6,000 Da, at least 7,000 Da, or at least 8,000 Da. Each possibility represents an independent embodiment. According to some embodiments, the third polymer has a MW of at most 1,000 Da, at most 2,000 Da, at most 3,000 Da, at most 4,000 Da, at most 5,000 Da, at most 6,000 Da, at most 7,000 Da, or at most 10,000 Da. Each possibility represents an independent embodiment.
[0141] In some embodiments, the v / v ratio of the third polymer in the casing is 10-90%. In some embodiments, the v / v ratio of the third polymer in the casing is 10-20%, 10-50%, 10-70%, 10-90%, 20-50%, 20-70%, 20-90%, 50-70%, 50-90%, or 70-90%. Each possibility represents an independent embodiment. In some embodiments, the v / v ratio of the third polymer in the casing is less than 20%, less than 40%, less than 50%, less than 70%, or less than 90%. Each possibility represents an independent embodiment.
[0142] In some embodiments, the length of the third polymer is substantially similar to the length of the first or second polymeric linker. In some embodiments, the length of the third polymer is substantially similar to the length of the first polymeric linker. In some embodiments, the length of the third polymer is substantially similar to the length of the polymeric linker (first or second) that is longer than the other polymeric linker. In some embodiments, the molecular weight of the third polymer is substantially similar to the molecular weight of the first or second polymeric linker. In some embodiments, the molecular weight of the third polymer is substantially similar to the molecular weight of the first polymeric linker. In some embodiments, the molecular weight of the third polymer is substantially similar to the molecular weight of the polymeric linker (first or second) that is higher than the other polymeric linker.
[0143] Without being limited by theory or mechanism of action, the effectiveness of the nanodelivery system of the present invention also depends on the molar ratio of different polymeric linkers, wherein the ratio defines the density of the brain-mediated transporter components and the active agent in the delivery system.
[0144] In some embodiments, the first polymeric linker comprises approximately 5-70% mol, 5-60% mol, 8-60% mol, 10-60% mol, 10-50% mol, 10-40% mol, 10-30% mol, 10-25% mol, 10-20% mol, 15-50% mol, 15-40% mol, 15-30% mol, 15-25% mol of the total polymer bound to the nanoparticles. 15-20% mol, 2-10% mol, 2-20% mol, 2-50% mol, 2-60% mol, 2-70% mol, 5-10% mol, 5-20% mol, 5-70% mol, 10-20% mol, 10-50% mol, 10-70% mol, 30-50% mol, 30-60% mol, 30-70% mol, 50-60% mol, or 50-70% mol. Each possibility represents an independent embodiment of the invention. In some embodiments, the first polymeric linker accounts for at least 2% mol, at least 4% mol, at least 5% mol, at least 6% mol, at least 8% mol, at least 10% mol, at least 12% mol, at least 15% mol, at least 18% mol, at least 20% mol, at least 25% mol, at least 30% mol, at least 35% mol, at least 40% mol, at least 50% mol, or at least 60% mol of the total polymer bound to the nanoparticles. Each possibility represents an independent implementation method.
[0145] In some embodiments, the second polymeric linker comprises approximately 5-70% mol, 5-60% mol, 10-60% mol, 10-55% mol, 10-50% mol, 10-40% mol, 10-30% mol, 10-25% mol, 10-20% mol, 15-60% mol, 15-55% mol, 15-50% mol, 15-45% mol, 15-40% mol, and 15-30% mol of the total polymer bound to the nanoparticles. 15-25% mol, 15-20% mol, 2-10% mol, 2-20% mol, 2-50% mol, 2-60% mol, 2-70% mol, 5-10% mol, 5-20% mol, 10-20% mol, 10-50% mol, 10-70% mol, 20-50% mol, 20-40% mol, 30-50% mol, 30-60% mol, 30-70% mol, 50-60% mol, or 50-70% mol. Each possibility represents an independent embodiment of the invention. In some embodiments, the second polymeric linker comprises at least 2% mol, at least 4% mol, at least 5% mol, at least 6% mol, at least 8% mol, at least 10% mol, at least 12% mol, at least 15% mol, at least 18% mol, at least 20% mol, at least 25% mol, at least 30% mol, at least 35% mol, at least 40% mol, at least 50% mol, or at least 60% mol of the total polymer bound to the nanoparticles. Each possibility represents an independent embodiment.
[0146] In some embodiments, the third polymer comprises approximately 5-90% mol, 5-85% mol, 5-80% mol, 10-80% mol, 20-78% mol, 25-75% mol, 30-75% mol, 40-75% mol, 50-75% mol, 60-75% mol, 60-70% mol, 60-80% mol, 5-60% mol, 10-60% mol, 10-55% mol, 10-50% mol, 10-40% mol, 15-60% mol, 15-55% mol, 15-50% mol, 15-45% mol, or 15-40% mol of the total polymer bound to the nanoparticles. Each possibility represents an independent embodiment of the invention. In some embodiments, the third polymer comprises between 60-80% mol of the total polymer bound to the nanoparticles. In some embodiments, the third polymer comprises between 50 and 80% mol of the total polymer bound to the nanoparticles. In some embodiments, the third polymer comprises at least 2% mol, at least 4% mol, at least 5% mol, at least 6% mol, at least 8% mol, at least 10% mol, at least 12% mol, at least 15% mol, at least 18% mol, at least 20% mol, at least 25% mol, at least 30% mol, at least 35% mol, at least 40% mol, at least 45% mol, at least 50% mol, at least 55% mol, at least 60% mol, at least 65% mol, or at least 70% mol of the total polymer bound to the nanoparticles. Each possibility represents an independent embodiment.
[0147] In some embodiments, the first polymeric linker comprises about 15 to 45% mol of the total polymer bound to the nanoparticles, the second polymeric linker comprises about 10 to 45% mol, and the third polymer comprises about 40 to 75% mol.
[0148] It should be understood that the %mol of each polymer component depends on the other polymer components bound to the nanoparticles, such that the total %mol of the polymer does not exceed 100%.
[0149] In some embodiments, the (w / w / w) ratio of the first polymeric linker, the second polymeric linker, and the third polymer is at least 5:5:90 to 60:30:30.
[0150] In some embodiments, the (w / w) ratio of the first polymer and the second polymer is at least 40:60 to 95:5.
[0151] According to the principles of the present invention, the nanodelivery system comprises a brain-mediated transporter component coupled to the first polymeric linker. The term "brain-mediated transporter component," which may be used interchangeably herein with the term "brain-mediated component," refers to a molecule capable of specifically binding to receptors or surface proteins expressed by cellular components of the brain border (BBB). The three main cellular elements that together form the brain microvessels of the BBB are brain endothelial cells, astrocyte terminale cells, and pericytes (PCs). In some embodiments, the brain-mediated transporter component may bind to receptors or surface proteins expressed by brain endothelial cells. In some embodiments, the brain-mediated transporter component may bind to receptors or surface proteins expressed by astrocyte terminale cells. In some embodiments, the brain-mediated transporter component may bind to receptors or surface proteins expressed by pericytes (PCs). Without wishing to be limited by any theory or mechanism, it is assumed that the brain-mediated component facilitates the transport of the entire nanodelivery system across the BBB, possibly through receptor-mediated transcytosis (RMT) or receptor-mediated endocytosis (RME) mechanisms.
[0152] In some embodiments, the brain-internalizing component is selected from, but not limited to, insulin, antibodies specifically targeting the insulin receptor, transferrin, antibodies specifically targeting the transferrin receptor, peptides specifically binding to the transferrin receptor, peptides specifically binding to the insulin receptor, insulin-like growth factor 1, antibodies specifically targeting insulin-like growth factor receptor 1, peptides specifically binding to insulin-like growth factor receptor 1, apolipoprotein A1, B, or E, lactoferrin, angiopep-2, antibodies specifically targeting the low-density lipoprotein receptor or lipoprotein receptor-associated protein, peptides specifically binding to the low-density lipoprotein receptor or lipoprotein receptor-associated protein, antibodies specifically targeting the diphtheria toxin receptor, peptides specifically binding to the diphtheria toxin receptor, and BBB-penetrating cell-penetrating peptides (CPPs). Each possibility represents an independent embodiment of the invention. When used herein, the term "cell-penetrating peptide (CPP)" refers to a peptide having an enhanced ability to cross the cell membrane bilayer without causing significant lethal membrane damage. The term “BBB-penetrating CPP” refers to cell-penetrating peptides that can cross the membrane of BBB cells and thus penetrate into the brain (Zou, Li-li et al., Current neuropharmacology 11.2(2013):197-208, and Stallmans, Sofie et al., PloS one 10.10(2015):e0139652.).
[0153] Other cellular proteins known in the art that can promote transcytosis can also be used as components of the brain internalization process. In some embodiments, the brain internalization component is selected from insulin, transferrin, low-density lipoprotein, apolipoprotein A1, B or E, and lactoferrin. Each possibility represents an independent embodiment of the invention. In some embodiments, the brain internalization component is selected from insulin and transferrin. In some embodiments, the brain internalization component is insulin. In some embodiments, the molecular weight (MW) of the insulin is about 5 kilodaltons (kD).
[0154] In some embodiments, the v / v ratio of the endogenous component (e.g., insulin) in the shell is between 2-10%, 2-20%, 2-50%, 2-60%, 2-70%, 5-10%, 5-20%, 5-50%, 5-60%, 5-70%, 10-20%, 10-50%, 10-60%, 10-70%, 30-50%, 30-60%, 30-70%, 50-60%, and 50-70%. In some embodiments, the v / v ratio of insulin in the shell is between 5-60%. In some embodiments, the v / v ratio of insulin in the shell is at least 2%, at least 5%, at least 10%, at least 30%, at least 50%, at least 60%, and at least 70%. Each possibility represents an independent implementation.
[0155] According to the principles of the invention, the second polymeric linker is coupled to an active pharmaceutical agent selected from bioactive molecules and labeled molecules. When used herein, the term "active pharmaceutical agent" means an agent intended to be delivered to the brain of a subject and capable of being used as a therapeutic or diagnostic agent. According to some embodiments, the active pharmaceutical agent is characterized by poor BBB penetration. According to some embodiments, after crossing the BBB, the active pharmaceutical agent can further target the nanodelivery system to specific regions in the brain, such as the hippocampus, striatum, cerebellum, and cortex. According to some embodiments, after crossing the BBB, the active pharmaceutical agent can target the nanodelivery system to specific cell populations in the brain, such as glioma cells, microglia, and neurons.
[0156] In some embodiments, the active pharmaceutical agent is a macromolecule. As defined herein, the term "macromolecule" refers to a very large molecule typically formed by the polymerization of monomers. In some embodiments, the macromolecule is a protein. In some embodiments, the macromolecule is an enzyme.
[0157] In some embodiments, the macromolecule is an antibody. When used herein, the term "antibody" refers to a polypeptide or group of polypeptides comprising at least one binding domain formed by the folding of a polypeptide chain, the binding domain being a three-dimensional binding space having an inner surface shape and charge distribution complementary to the characteristics of the antigenic determinants of the antigen. Antibodies typically exist in tetrameric form, comprising two identical pairs of polypeptide chains, each pair having one "light" chain and one "heavy" chain. Variable regions of each light / heavy chain pair form the binding site of the antibody. Antibodies can be oligoclonal, polyclonal, monoclonal, chimeric, camelified, CDR-transplanted, multispecific, bispecific, catalytic, humanized, all-human, anti-idiotype antibodies, and can be labeled as soluble or bound in a soluble form, as well as fragments including epitope-binding fragments, their variants, or derivatives, which are alone or in combination with other amino acid sequences. Antibodies can be derived from any species. The term antibody also includes binding fragments, including but not limited to Fv, Fab, Fab', F(ab')2, single-chain antibodies (svFC), dimerized variable regions (diabody), and disulfide-linked variable regions (dsFv). Specifically, antibodies include immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, i.e., molecules containing antigen-binding sites. Antibody fragments may or may not fuse to another immunoglobulin domain, including but not limited to the Fc region or fragments thereof. Those skilled in the art will further recognize that other fusion products can be generated, including but not limited to scFv-Fc fusions, variable region (e.g., VL and VH)–Fc fusions, and scFv-scFv-Fc fusions.
[0158] In some embodiments, the active agent coupled to the second polymeric linker is a bioactive molecule. In some embodiments, the bioactive molecule is adjacent to the second polymeric linker. As used herein, the term "bioactive molecule" refers to a compound or molecule capable of inducing or altering a biological response in a system. In some embodiments, the bioactive molecule is a therapeutic agent. In some embodiments, the bioactive molecule has a therapeutic application. In some embodiments, the bioactive molecule has a diagnostic application. In some embodiments, the bioactive molecule has both therapeutic and diagnostic applications.
[0159] In some embodiments, the bioactive molecule comprises small molecules, macromolecules, oligonucleotides, antisense RNA peptides, or any combination thereof. In some embodiments, the bioactive molecule is selected from macromolecules, peptides, and small molecules. In some embodiments, the bioactive molecule is selected from antibodies, peptides, and small molecules. Each possibility represents an independent embodiment of the invention.
[0160] When used herein, the term “peptide” refers to any polymeric compound formed by the formation of an amide bond between the α-carboxyl group of one D- or L-amino acid and the α-amino group of another D- or L-amino acid.
[0161] When used herein, the term "small molecule" refers to a synthetic or naturally occurring organic or inorganic molecule, typically having a molecular weight of less than 1000 Da. The term "small molecule" also encompasses any fragment of a peptide, protein, or antibody, including natural sequences and variants falling within the aforementioned molecular weight range.
[0162] In some embodiments, the bioactive molecule is a therapeutic agent effective in treating brain-related diseases or disorders. In some embodiments, the bioactive molecule is an antibody used for the treatment or diagnosis of brain-related diseases.
[0163] When used in this document, the term “brain-related disease or disorder” means any disease or disorder that causes dysfunction of the brain or any of its cells. Non-limiting examples of brain-related diseases and disorders include neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and dementia; neuromuscular diseases such as amyotrophic lateral sclerosis (ALS) and motor neuron disease; neurodevelopmental disorders such as autism spectrum disorder and attention deficit hyperactivity disorder (ADHD); autoimmune brain-related diseases such as multiple sclerosis (MS); neuropsychiatric disorders such as schizophrenia, substance addiction, smoking addiction, eating disorders, obsessive-compulsive disorder, various forms of depression, anxiety disorders, cognitive impairment, and affective disorders; epileptic disorders such as epilepsy; pain disorders such as migraine; cerebrovascular diseases including traumatic brain injury and stroke; brain-related cancers such as brain and nerve tumors, brain metastases, gliomas, glioblastoma (GBM), and gliosarcoma (GS); neurogenetic diseases such as Huntington's disease, Kennedy's disease, metabolic disorders, lysosomal storage diseases, and Duchenne's disease; and neuroinfectious diseases.
[0164] In some embodiments, the active pharmaceutical agent is a labeled molecule. When used herein, the term "labeled molecule" refers to a molecule capable of producing a signal detectable by suitable detection means, such as, but not limited to, radioactive molecules and fluorescent molecules. In some embodiments, the labeled molecule has diagnostic applications. In some embodiments, the labeled molecule is a diagnostic agent. In some embodiments, the labeled molecule comprises a small molecule, a large molecule, an oligonucleotide, antisense RNA, a peptide, or any combination thereof. In some embodiments, the labeled molecule is a small molecule. In some embodiments, the labeled molecule is an antibody.
[0165] In some embodiments, the active pharmaceutical agent is an antibody having a molecular weight (MW) of 100-120 kD, 100-150 kD, 100-200 kD, 100-250 kD, 150-200 kD, 150-250 kD, or 200-250 kD. Each possibility represents an independent embodiment. In some embodiments, the antibody has a MW of at least 100 kD, at least 110 kD, at least 120 kD, at least 130 kD, at least 140 kD, at least 150 kD, at least 160 kD, at least 180 kD, at least 200 kD, or at least 250 kD. Each possibility represents an independent embodiment. In some embodiments, the antibody has a MW of 150-200 kD. In some embodiments, the antibody has a MW of 130-180 kD. In some embodiments, the antibody has a MW of 140-160 kD.
[0166] In some embodiments, the antibody has a molecular weight (MW) of 150-200 kDa, and the second polymeric linker (PEG) has a MW of at least 2,000 Da, at least 2,500 Da, or at least 3,000 Da. In some embodiments, the antibody has a MW of 150-200 kDa, and the second polymeric linker (PEG) has a MW of at most 2,000 Da, at most 2,500 Da, at most 3,000 Da, at most 3,500 Da, at most 4,000 Da, at most 5,000 Da, or at most 6,000 Da. In some such embodiments, the endocrinogenic component is insulin with a MW of 5-6 kDa, and the first polymeric linker has a MW of at least 2,000 Da, at least 2,500 Da, at least 3,000 Da, at least 3,400 Da, at least 4,000 Da, or at least 4,500 Da.
[0167] In some embodiments, the v / v ratio of the antibody in the shell is between 2-10%, 2-20%, 2-30%, 2-40%, 5-10%, 5-20%, 5-30%, 5-40%, 10-20%, 10-30%, 10-40%, 20-30%, 20-40%, and 30-40%. In some embodiments, the v / v ratio of the antibody in the shell is between 5-30%. In some embodiments, the v / v ratio of the antibody in the shell is at least 2%, at least 5%, at least 10%, at least 30%, and at least 40%. Each possibility represents an independent embodiment.
[0168] In some embodiments, the v / v ratio of the macromolecules in the shell is between 2-10%, 2-20%, 2-30%, 2-40%, 5-10%, 5-20%, 5-30%, 5-40%, 10-20%, 10-30%, 10-40%, 20-30%, 20-40%, and 30-40%. In some embodiments, the v / v ratio of the macromolecules in the shell is between 5-30%. In some embodiments, the v / v ratio of the macromolecules in the shell is at least 2%, at least 5%, at least 10%, at least 30%, and at least 40%. Each possibility represents an independent embodiment.
[0169] In some embodiments, the active pharmaceutical ingredient has a molecular weight (MW) of less than 1,000 Daltons (Da). In some embodiments, the active molecule has a MW of 10-50 Da, 10-100 Da, 10-500 Da, 10-1,000 Da, 50-100 Da, 50-500 Da, 50-1,000 Da, 100-300 Da, 100-500 Da, 100-800 Da, 100-1,000 Da, 500-800 Da, 500-1,000 Da, or 800-1,000 Da. Each possibility represents an independent embodiment.
[0170] In some embodiments, the active pharmaceutical ingredient has a molecular weight (MW) of less than 1,000 Da, less than 900 Da, less than 800 Da, less than 700 Da, less than 600 Da, less than 500 Da, less than 400 Da, less than 300 Da, less than 200 Da, or less than 100 Da. Each possibility represents an independent embodiment. In some embodiments, the active pharmaceutical ingredient has a MW of greater than 100 Da, greater than 200 Da, greater than 300 Da, greater than 400 Da, greater than 500 Da, greater than 600 Da, greater than 700 Da, greater than 800 Da, or greater than 900 Da. Each possibility represents an independent embodiment.
[0171] In some embodiments, the active pharmaceutical agent is a small molecule. In some embodiments, the bioactive molecule is a small molecule. In some embodiments, the bioactive molecule is an oligonucleotide. In some embodiments, the bioactive molecule is antisense RNA. In some embodiments, the bioactive molecule is a peptide. In some embodiments, the bioactive molecule is a drug.
[0172] In some embodiments, the v / v ratio of the bioactive molecule in the shell is 40-95%. In some embodiments, the v / v ratio is between 30-40%, 30-50%, 30-70%, 30-90%, 30-95%, 30-98%, 40-50%, 40-70%, 40-90%, 40-95%, 40-98%, 60-70%, 60-90%, 60-95%, 60-98%, 70-90%, 70-95%, 70-98%, 80-90%, 80-95%, and 80-98%. Each possibility represents an independent implementation.
[0173] According to some embodiments, the inorganic nanoparticles are gold nanoparticles. According to some embodiments, the first linear polymeric linker is a thiolated PEG5000 acid or a thiolated PEG5000 amine. According to some embodiments, the second linear polymeric linker is a thiolated PEG3500 acid or a thiolated PEG3500 amine. According to some embodiments, the brain-mediated transporter component is insulin. The nanodelivery system may also include an active pharmaceutical agent selected from antibodies, peptides, and small molecules.
[0174] According to some embodiments, the inorganic nanoparticles are iron oxide nanoparticles. According to some embodiments, the first linear polymeric linker is a thiolated PEG5000 acid or a thiolated PEG5000 amine. According to some embodiments, the second linear polymeric linker is a thiolated PEG3500 acid or a thiolated PEG3500 amine. According to some embodiments, the brain-mediated transporter component is insulin. The nanodelivery system may also include an active pharmaceutical agent selected from antibodies, peptides, and small molecules.
[0175] According to some embodiments, the inorganic nanoparticles are gold nanoparticles. According to some embodiments, the first linear polymeric linker is a thiolated PEG5000 acid or a thiolated PEG5000 amine. According to some embodiments, the second linear polymeric linker is a thiolated PEG3500 acid or a thiolated PEG3500 amine. According to some embodiments, the brain-mediated transporter component is transferrin. The nanodelivery system may also include an active pharmaceutical agent selected from antibodies, peptides, and small molecules.
[0176] According to some embodiments, the inorganic nanoparticles are gold nanoparticles. According to some embodiments, the first linear polymeric linker is a thiolated PEG1000 acid or a thiolated PEG1000 amine. According to some embodiments, the second linear polymeric linker is a thiolated PEG5000 acid or a thiolated PEG5000 amine. According to some embodiments, the brain-mediated transporter component is insulin. The nanodelivery system may also include an active pharmaceutical agent selected from antibodies, peptides, and small molecules.
[0177] Preparation method
[0178] According to another aspect, a method for preparing the nanodelivery system of the present invention as described in all embodiments above is provided, the method comprising the following sequential steps:
[0179] a) The surface of the inorganic nanoparticles is partially coated with the first linear polymeric linker, and then the first linear polymeric linker is coupled to the brain-mediated transporter component; and
[0180] b) Partially coat the surface of the inorganic nanoparticles with the second linear polymeric linker, and then couple the second linear polymeric linker to the active pharmaceutical ingredient.
[0181] Steps (a) and (b) can be performed in any order.
[0182] When used herein, the term "partially coated" refers to coupling a plurality of respective polymeric linkers to the surface of a nanoparticle such that the plurality of linkers partially cover the surface of the nanoparticle at a density level below the saturation level of the bare nanoparticle.
[0183] The amount of polymer required to achieve full density (i.e., 100%) coating of the nanoparticles, and thus the amount required for partial coating, can be determined using any method known in the art. For example, adding different amounts of polymer to the nanoparticle solution and measuring the concentration of free polymer in the supernatant after centrifugation is a widely used method. Alternatively, any characterization method sensitive to changes in coating density, such as zeta potential and DLS, can be used. Furthermore, the amount of polymer required to achieve complete coating can be determined theoretically based on the surface area of the nanoparticles. For example, it has previously been shown that thiol-PEG molecules occupy 0.35 nm on the surface of gold nanoparticles. 2 The footprint area (Qian, Ximei et al., Nature Biotechnology 26.1(2008):83-90). Therefore, the amount of thiol-PEG linker required to cover 100% of the gold nanoparticle surface can be calculated based on the average diameter of the GNP.
[0184] In some embodiments, each of the first and second linear polymeric linkers is added in an amount suitable for covering the surface of the inorganic nanoparticles between 5% and 60%.
[0185] In some embodiments, step (a) includes coating the surface of the inorganic nanoparticles with 5%-60%, 10-60%, 10-50%, 10-40%, 10-30%, 10-25%, 10-20%, 15-50%, 15-40%, 15-30%, 15-25%, 15-20%, 2-10%, 2-20%, 2-50%, 2-60%, 2-70%, 5-10%, 5-20%, 5-70%, 10-20%, 10-50%, 10-70%, 30-50%, 30-60%, 30-70%, 50-60%, or 50-70%. (Editor's note: The original text included mol.)
[0186] In some embodiments, step (b) includes coating the surface of the inorganic nanoparticles with 5%-60%, 10-60%, 10-50%, 10-40%, 10-30%, 10-25%, 10-20%, 15-50%, 15-40%, 15-30%, 15-25%, 15-20%, 2-10%, 2-20%, 2-50%, 2-60%, 2-70%, 5-10%, 5-20%, 5-70%, 10-20%, 10-50%, 10-70%, 30-50%, 30-60%, 30-70%, 50-60%, or 50-70%. (Editor's note: The original text included mol.)
[0187] In some embodiments, the method further includes coating the surface of the inorganic nanoparticles with a third polymeric linker portion, wherein the polymeric linker is a single-function linker.
[0188] In some embodiments, step (a) is performed before step (b). In some embodiments, the method further includes centrifugation between step (a) and step (b). In other embodiments, step (a) is performed after step (b). In some embodiments, the method further includes centrifugation between step (b) and step (a). In some embodiments, the active pharmaceutical agent is an antibody or peptide, and step (a) is performed before step (b). In some embodiments, the active pharmaceutical agent is a small molecule, and step (a) is performed after step (b).
[0189] The nanoparticles, first polymeric linkers, second polymeric linkers, brain-mediated transporter components, and active agents suitable for use in the preparation method described above are those described in the various aspects and embodiments of the nanodelivery system.
[0190] Pharmaceutical Composition
[0191] On the other hand, a pharmaceutical composition is provided comprising a nanodelivery system and a pharmaceutically acceptable carrier according to various embodiments described above.
[0192] When used herein, “pharmaceutical formulation,” “pharmaceutical composition,” or “medicinal composition” can include any of a variety of carriers, such as solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delay agents, salts, preservatives, pharmaceuticals, pharmaceutical stabilizers, gels, binders, excipients, disintegrants, lubricants, sweeteners, flavorings, dyes, and similar materials and combinations thereof, as will be known to those skilled in the art (Remington's, 1990). Pharmaceutical compositions containing the nanoparticles described herein as active ingredients can be prepared using conventional pharmaceutical compounding techniques. See, for example, Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Co., Easton, Pa. (1990). See also Remington: The Science and Practice of Pharmacy, 21st edition, Lippincott Williams & Wilkins, Philadelphia, Pa. (2005).
[0193] Depending on whether the composition is to be administered in solid, liquid, or aerosol form, and whether sterility is required for routes of administration such as injection, the composition may contain different types of carriers. Those skilled in the art will be familiar with techniques for producing sterile solutions for injection or administration via any other route. Sterile injectable solutions are prepared by incorporating the active compound in the desired amount along with a variety of other ingredients familiar to those skilled in the art into a suitable solvent.
[0194] Based on the weight of the pharmaceutical composition presented herein, the carrier may comprise a total of about 0.1% to about 99.99999%.
[0195] According to some embodiments, the pharmaceutical composition is formulated for systemic administration. According to some embodiments, the pharmaceutical composition is formulated for systemic administration selected from intravenous and intranasal administration. According to some embodiments, the pharmaceutical composition is formulated for intravenous administration. According to some embodiments, the pharmaceutical composition is formulated for intranasal administration. According to some embodiments, the pharmaceutical composition is formulated for intrathecal administration.
[0196] The compositions envisioned herein may take the form of solutions, suspensions, emulsions, aerosols, combinations thereof, or any other pharmaceutically acceptable compositions commonly known in the art.
[0197] In some embodiments, the carrier is a solvent. As a non-limiting example, the composition may be formulated in the solvent. Such solvents include any suitable solvents known in the art, such as water, brine, or phosphate-buffered saline.
[0198] The formulation of the composition can vary depending on the route of administration. For example, for parenteral administration in an aqueous solution, the solution should be appropriately buffered if necessary, and the liquid diluent should first be isotonic with sufficient saline or glucose. According to this disclosure, sterile aqueous media that can be used will be known to those skilled in the art.
[0199] Complementary active ingredients may also be incorporated into the composition. For human administration, the formulation should meet the sterility and overall safety and purity standards required by the FDA Office of Biologics Standards. It may be administered via any known route.
[0200] In some embodiments, the pharmaceutical composition comprises at least about 0.001 g to about 1 g of the particles disclosed herein per kilogram of subject.
[0201] The pharmaceutical composition may contain a variety of antioxidants to delay the oxidation of one or more components. Furthermore, preservatives may be used to prevent microbial activity, such as various antibacterial and antifungal agents, including but not limited to parabens (e.g., methylparaben, propylparaben), chlorobutanol, phenol, sorbic acid, thimerosal, or combinations thereof. The composition must be stable under manufacturing and storage conditions and resistant to contamination by microorganisms such as bacteria and fungi. It should be recognized that exotoxin contamination should be maintained at at least safe levels, such as less than 0.5 ng / mg protein.
[0202] In embodiments where the composition is in liquid form, the carrier may be a solvent or dispersion medium, including but not limited to water, ethanol, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.), lipids (e.g., triglycerides, vegetable oils, liposomes), and combinations thereof. In many cases, isotonic agents such as sugars, sodium chloride, or combinations thereof are preferred.
[0203] In other embodiments, nasal solutions or sprays, aerosols, or inhalers may be used. Nasal solutions are typically designed as aqueous solutions to be applied to the nasal passages in the form of drops or sprays.
[0204] Solid compositions for oral administration are also envisioned. In these embodiments, the solid compositions may include, for example, solutions, suspensions, emulsions, tablets, pills, capsules, sustained-release formulations, buccal compositions, lozenges, elixirs, suspensions, syrups, or combinations thereof.
[0205] Sterile injectable solutions are prepared by incorporating an active compound (e.g., nanoparticles) in the desired amount along with various other ingredients listed above into a suitable solvent. If necessary, the liquid medium can be appropriately buffered, and the liquid diluent can be isotonicized with sufficient saline or glucose before injection.
[0206] Repeated administration may be necessary, as determined by those skilled in the art. Therefore, in some embodiments of the methods described herein, a single dose is contemplated. In other embodiments, two or more doses are contemplated. When more than one dose is administered to a subject, the time interval between doses may be any time interval determined by those skilled in the art.
[0207] Therapeutic and diagnostic uses of the composition
[0208] According to some embodiments, the pharmaceutical composition is used to prevent disease in subjects in need. According to some embodiments, the pharmaceutical composition is used to treat disease in subjects in need. According to some embodiments, the pharmaceutical composition is used to monitor disease in subjects in need. In some embodiments, the disease is a brain-related disease or disorder.
[0209] In some embodiments, the disease is a central nervous system disease. According to some embodiments, the disorder is a brain disorder.
[0210] In some embodiments, the pharmaceutical composition is used to treat brain-related diseases or disorders. In some embodiments, the brain-related diseases or disorders are selected from brain-related cancers, neurodegenerative disorders, neuromuscular diseases, neurodevelopmental disorders, autoimmune brain-related diseases, neuropsychiatric disorders, epilepsy, pain disorders, cerebrovascular diseases, neurogenetic diseases, and neuroinfectious diseases.
[0211] In some embodiments, the brain-related disease is a brain-related cancer. When used herein, the term "brain-related cancer" encompasses both primary brain tumors and metastatic brain tumors. In some embodiments, the brain-related cancer is selected from, but not limited to, brain and nerve tumors, brain metastases, gliomas, glioblastomas (GBM), and gliosarcomas (GS). In some embodiments, the brain-related disease is a neurodegenerative disorder. In some embodiments, the neurodegenerative disorder is selected from Parkinson's disease, Alzheimer's disease, Huntington's disease, and dementia. In some embodiments, the brain-related disease is a neuromuscular disease. In some embodiments, the neuromuscular disease is selected from amyotrophic lateral sclerosis (ALS) and motor neuron disease. In some embodiments, the brain-related disease is a neurodevelopmental disorder. In some embodiments, the neurodevelopmental disorder is selected from autism spectrum disorder and attention deficit hyperactivity disorder (ADHD). In some embodiments, the brain-related disease is multiple sclerosis (MS). In some embodiments, the brain-related disease is a neuropsychiatric disorder. In some embodiments, the neuropsychiatric disorder is selected from schizophrenia, drug addiction, smoking addiction, eating disorders, obsessive-compulsive disorder, various forms of depression, anxiety disorders, cognitive impairment, and affective disorders. In some embodiments, the brain-related disease is an epileptic disorder. In some embodiments, the epileptic disorder is epilepsy. In some embodiments, the brain-related disease is a pain disorder. In some embodiments, the brain-related disease is a cerebrovascular disease. In some embodiments, the cerebrovascular disease is selected from traumatic brain injury and stroke. In some embodiments, the brain-related disease is a neurogenetic disease. In some embodiments, the neurogenetic disease is selected from Huntington's disease, Kennedy's disease, metabolic disorders, lysosomal storage diseases, and Duchenne schizophrenia. In some embodiments, the brain-related disease is a neuroinfectious disease.
[0212] In some embodiments, the brain-related disease is Alzheimer's disease. In some embodiments, the brain-related disease is Parkinson's disease. According to some embodiments, the brain-related disease is Huntington's disease, spinocerebellar ataxia, amyotrophic lateral sclerosis (ALS), Friedreich ataxia, Lou Gehrig's disease, or spinal muscular atrophy. According to some embodiments, the brain-related disease is a prion disease.
[0213] When used herein, the term “subject” means any animal (e.g., a mammal), including but not limited to humans, non-human primates, rodents, etc. (e.g., a recipient of a particular treatment). Generally, the terms “subject” and “patient” are used interchangeably unless otherwise specified herein.
[0214] In some embodiments, the subject is a human subject. In some embodiments, the subject is at risk of having a brain-related disease, disorder, or medical condition. In some embodiments, the subject has been diagnosed with a brain-related disease, disorder, or medical condition. In some embodiments, the subject has been diagnosed with a brain-related genetic disorder. In some embodiments, the subject is at risk of having a neurodegenerative disease. In some embodiments, the subject has been diagnosed with a neurodegenerative disease. In some embodiments, the subject has been diagnosed with Alzheimer's disease. In some embodiments, the subject has been diagnosed with Parkinson's disease.
[0215] When used herein, a subject at risk of having a disease, disorder, or medical condition is a subject exhibiting one or more signs or symptoms indicative of a disease, disorder, or medical condition, or who is being screened for a disease, disorder, or medical condition (e.g., during a routine physical examination). A subject at risk of having a disease, disorder, or medical condition may also have one or more risk factors. A subject at risk of having a disease, disorder, or medical condition includes individuals who have not previously been tested for the aforementioned disease, disorder, or medical condition. However, a subject at risk of having a disease, disorder, or medical condition also includes individuals who have received a preliminary diagnosis but have not yet undergone confirmatory testing (e.g., biopsy and / or histology) or whose stage of the aforementioned disease, disorder, or medical condition is unknown. The term also includes persons who have previously had the aforementioned disease, disorder, or medical condition (e.g., individuals in remission).
[0216] Subjects at risk of developing a brain-related disease, disorder, or medical condition may be diagnosed with or found not to have the aforementioned brain-related disease, disorder, or medical condition.
[0217] When used herein, subjects diagnosed with brain-related diseases, disorders, or medical conditions may be diagnosed using any suitable method, including but not limited to biopsy, X-ray, blood tests, and the diagnostic methods of this invention. A “preliminary diagnosis” is a diagnosis based solely on visual (e.g., CT scan or the presence of a mass) and antigen testing.
[0218] In some embodiments, the subject suffers from a brain-related disease, disorder, or medical condition, and the imaging method is used to determine the stage of the disease, disorder, or medical condition. In some embodiments, the subject suffering from a brain-related disease, disorder, or medical condition is treated with medication, and the imaging method is used to track the treatment.
[0219] When used herein, the term “treatment” or “improvement” for a disease, disorder, or condition means the reduction of at least one symptom, a decrease in its severity, or an inhibition of its progression. Treatment does not necessarily mean that the disease, disorder, or condition is completely cured. The useful compositions described herein are effective treatments simply by reducing the severity of the disease, disorder, or condition, reducing the severity of associated symptoms, or providing an improvement in the quality of life of the patient or subject.
[0220] In some embodiments, the present invention provides a method for administering an active pharmaceutical agent to a subject in need to prevent, treat, and / or monitor brain-related diseases, the method comprising administering to the subject a pharmaceutical composition comprising the nanodelivery system described in all embodiments of the present invention. According to some currently preferred embodiments, the method comprises delivering the active pharmaceutical agent to a brain region of the subject.
[0221] In some embodiments, the method further includes the step of imaging a brain region of the subject to assess the accumulation of the nanodelivery system in the subject's brain. In some embodiments, the imaging is performed using an imaging system selected from: computed tomography (CT), X-ray imaging, magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT), ultrasound (US), and any combination thereof.
[0222] In some embodiments, the present invention provides a therapeutic diagnostic method. The method includes administering the pharmaceutical composition of the present invention to a subject in need and imaging a target site in the subject to determine whether the nanoparticles accumulate at the target site. In some embodiments, the target site is a site in the subject's brain.
[0223] In some embodiments, the composition may be administered to a subject using any method known to those skilled in the art. The route of administration may vary depending on the application. For example, the route of administration may vary depending on the specific cells, brain region, or subject to be imaged. For example, the composition may be administered intravenously, intracerebrally, intracranially, intrathecally, intraventricularly, in the substantia nigra or substantia nigra region, intradermally, intraarterially, intraperitoneally, intralesionally, intratracheally, intranasally, intramuscularly, intraperitoneally, subcutaneously, orally, locally, by inhalation (e.g., aerosol inhalation), by injection, by infusion, subarachnoid infusion, transmucosal infusion, intracarotid infusion, continuous infusion, local perfusion of target cells by direct immersion, via catheter, by irrigation, or by other methods or any combination of the above methods, as known to those skilled in the art.
[0224] In some embodiments, the pharmaceutical composition is administered to the subject via a systemic route. In some embodiments, the systemic administration is selected from intravenous (IV) and intranasal (IN) administration. In some embodiments, the pharmaceutical composition is administered to the subject via intrathecal (IT) administration.
[0225] In some embodiments, the particles are administered intravenously. In some embodiments, the particles are administered intranasally.
[0226] After formulation, the composition will be administered in a manner compatible with the dosage formulation and in an effective amount. For example, the nanoparticles can be administered in an effective amount for a specific imaging application.
[0227] The effective amount of the pharmaceutical composition is determined based on the intended target, such as the imaging method and the subject or part of the subject to be imaged. The amount to be administered may also vary depending on the specific route of administration. The composition is preferably administered in a “safe and effective amount.” When used herein, the term “safe and effective amount” means an amount of composition sufficient to achieve the intended target (e.g., imaging) without excessive adverse side effects (e.g., toxicity, irritation, or allergic reactions).
[0228] In some embodiments, imaging of the target site is performed using imaging techniques that utilize penetrating radiation. According to some embodiments, the imaging technique is selected from magnetic resonance imaging (MRI), computed tomography (CT), X-ray imaging, positron emission tomography (PET), single-photon emission computed tomography (SPECT), and ultrasound (US).
[0229] In some embodiments, the imaging step is performed 0.5 to 96 hours after the administration step. In some embodiments, the imaging step is performed 0.5 to 48 hours after the administration step. In some embodiments, the imaging step is performed 0.5 to 24 hours after the administration step. In some embodiments, the imaging step is performed 0.5 to 12 hours after the administration step. In some embodiments, the imaging step is performed 1 to 12 hours after the administration step. In some embodiments, the imaging step is performed 1 to 6 hours after the administration step. In some embodiments, the imaging step is performed within 96 hours of the administration step. In some embodiments, the imaging step is performed within 48 hours of the administration step. In some embodiments, the imaging step is performed within 24 hours of the administration step. In some embodiments, the imaging step is performed within 12 hours of the administration step. In some embodiments, the imaging step is performed within 6 hours of the administration step.
[0230] In some embodiments, the method includes the step of determining whether the nanoparticles accumulate at a target site in the subject. In some embodiments, the treatment decision may be not to administer treatment. In some embodiments, analysis of the imaging data is used to determine the appropriate treatment approach for the patient. In some embodiments, the determination of the appropriate treatment approach for the patient depends on, for example, the stage of the disease, disorder, or medical condition, and the patient's health status. In some embodiments, the treatment approach includes one or more treatment options selected from intravenous, intranasal, intraperitoneal, intramuscular, and subcutaneous, as well as any other biological or inorganic product intended for treatment. In some embodiments, treatment is administered after imaging. In some embodiments, treatment is administered to the subject in real time while the subject is being imaged.
[0231] In some embodiments, imaging and treatment of the subject are performed simultaneously. In some embodiments, the bioactive molecules can be activated at target sites in the subject after imaging.
[0232] medicine box
[0233] In some embodiments, the present invention provides a kit comprising one or more compositions disclosed herein. In some embodiments, the present invention provides a kit for use with the methods disclosed herein. For example, the kit may include a container having a sterile reservoir for containing any of the compositions disclosed herein. In some embodiments, the kit further includes instructions for use. For example, the kit may include instructions for administering the composition to a subject (e.g., indications, dosage, method, etc.). In yet another example, the kit may include instructions for applying the compositions and methods of the present invention to an imaging system, such as computed tomography (CT), ultrasound (US), or magnetic resonance imaging (MRI).
[0234] The description of various embodiments of the present invention is presented for illustrative purposes and is not intended to be exhaustive or limited to the disclosed embodiments. Many modifications and variations will be apparent to those skilled in the art without departing from the scope and spirit of the described embodiments. The terminology used herein has been selected to best explain the principles of the embodiments, their practical application, or technical improvements compared to technologies found in the market, or to enable others skilled in the art to understand the embodiments disclosed herein.
[0235] Any concentration range, percentage range, or proportion range described herein should be understood to include any integer concentration, percentage, or proportion within the range and its fractions, such as one-tenth or one-hundredth of an integer, unless otherwise specified.
[0236] Any range of numbers described herein relating to any physical characteristic such as polymer subunits, size, or thickness should be understood to include any integers within the range described, unless otherwise specified.
[0237] When used herein, the term “about” in combination with a value means the reference value plus or minus 10%. For example, a molecular weight of about 1000 Da means a molecular weight of 1000 Da ± 100 Da.
[0238] It should be noted that, when used herein and in the appended claims, the singular forms “an,” “a,” and “the” include plural designations unless the context explicitly states otherwise. Thus, for example, the designation “polynucleotide” includes a plurality of such polynucleotides, and the designation “polypeptide” includes designations for one or more polypeptides and their equivalents known to those skilled in the art, and so on. It should also be noted that a claim may be drafted to exclude any optional elements. Therefore, this statement is intended to serve as a priori basis for the use of exclusive terms such as “unique,” “only,” etc., or the use of “negative” restrictions in conjunction with the description of the elements of the claim.
[0239] The term “multiple” means “two or more” unless explicitly stated otherwise.
[0240] When using idioms such as "at least one of A, B, and C," this structure is generally intended to allow those skilled in the art to understand the meaning of the idiom (e.g., "a system having at least one of A, B, and C" will include, but is not limited to, systems having a single A, a single B, a single C, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.). Those skilled in the art will further understand that any transitional conjunctions and / or phrases that actually present two or more options, whether in the specification, claims, or drawings, should be understood to predicate on the possibility of including one, any, or both of the items. For example, the phrase "A or B" will be understood to include the possibility of "A" or "B" or "A and B."
[0241] It should be understood that certain features of the invention described in the context of a standalone implementation for clarity may also be provided in combination in a single implementation. Conversely, various different features of the invention described in the context of a single implementation for brevity may also be provided individually or in any suitable sub-combination. All combinations of embodiments belonging to the invention are specifically included in the invention and disclosed herein, as if each combination were individually and explicitly disclosed. Furthermore, all sub-combinations of various different embodiments and their elements are also specifically included in the invention and disclosed herein, as if each such sub-combination were individually and explicitly disclosed.
[0242] Other objects, advantages, and novel features of the invention will become apparent to those skilled in the art upon examination of the following embodiments, which are not intended to be limiting. Furthermore, each of the various embodiments and aspects of the invention claimed above and in the following claims section is experimentally supported in the embodiments described below.
[0243] The various embodiments and aspects of the invention as described above and claimed in the claims section below are experimentally supported in the examples below.
[0244] Example
[0245] Generally, the nomenclature used herein and the laboratory procedures used in this invention include molecular, biochemical, microbiological, and recombinant DNA technologies. These technologies are well explained in the literature. See, for example, *Molecular Cloning: A Laboratory Manual*, Sambrook et al., (1989); *Current Protocols in Molecular Biology*, Volumes I-III, edited by Ausubel, RM, (1994); Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Baltimore, Maryland (1989); Perbal, *A Practical Guide to Molecular Cloning*, John Wiley & Sons, New York (1988); Watson et al., *Recombinant DNA*, Scientific American Books, New York; Birren et al., eds., *Genome Analysis: A Laboratory Manual Series*, Volumes 1-4, Cold Spring Harbor Laboratory Press, New York. York (1998); the methods described in U.S. Patent Nos. 4,666,828, 4,683,202, 4,801,531, 5,192,659, and 5,272,057; Cell Biology: A Laboratory Handbook, Volumes I-III, edited by Cellis, JE (1994); Culture of Animal Cells: A Manual of Basic Technique, Freshney, Wiley-Liss, NY (1994), 3rd edition; Current Protocols in Immunology, Volumes I-III, edited by Coligan, JEEditor-in-Chief (1994); Stites et al., eds., *Basic and Clinical Immunology* (8th ed.), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi, eds., *Strategies for Protein Purification and Characterization—A Laboratory Course Manual*, CSHL Press (1996); all these references are incorporated by reference. Other general references are provided throughout this document.
[0246] Example 1: Preparation and characterization of gold nanoparticles (GNPs) coated with insulin and EGFR antibody (EGFR&Ins-GNPs)
[0247] Figure 1 A schematic diagram of a non-limiting example of the particles is shown, illustrating gold nanoparticles (GNPs) coated with a polymer layer comprising a first polymeric linker coupled to insulin (e.g., -S-PEG-C(O)-, ~5kDa), a second polymeric linker coupled to a bioactive molecule (e.g., -S-PEG-C(O)-, ~3.5kDa), and a monofunctional third polymeric component (e.g., -S-PEG-O-CH3 ~5kDa).
[0248] GNP synthesis
[0249] 20 nm spherical GNPs were prepared by citrate reduction of HAuCl4. 200 mL of distilled water containing a total of 414 μL of 50% w / v HAuCl4 solution was boiled in an oil bath on a heated plate with stirring. After boiling, 4.04 mL of 10% sodium citrate solution was added, and the mixture was boiled with stirring for another 10 minutes. The solution was removed from the plate and centrifuged after cooling to room temperature until nanoparticles precipitated.
[0250] Coupling of PEG5000 and insulin with GNPs
[0251] First, GNPs (85% of the particle surface area) were partially coated with mPEG-SH (~5 kDa; 70% of the particle surface area) and heterofunctional HS-PEG-COOH (~5 kDa; 15% of the particle surface area). The amounts of mPEG-SH and HS-PEG-COOH required for this partial coating were derived from theoretical calculations based on the following finding: thiol-PEG molecules occupy 0.35 nm on the surface of gold nanoparticles. 2The footprint area (Qian, Ximei et al., Nature biotechnology 26.1(2008):83-90). Coupling was performed by adding a mixture of HS-PEG-COOH (145 μl, 50 mg / ml) and mPEG-SH (677 μl, 50 mg / ml) to a GNP solution and mixing for two hours. The solution was then ultracentrifuged at 15,000 RPM for 20 min and then ultracentrifuged again at 20,000 RPM for 15 min. The precipitate containing PEG-coated GNPs (85% coating in total) was transferred to a vial. Insulin was then covalently coupled to the carboxyl group of HS-PEG-COOH by adding excess insulin along with EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HCl) and NHS (sodium N-hydroxysulfosuccinimide) on ice and mixing for two hours. The solution was then centrifuged at 14,000 RPM for 30 minutes (while maintaining a cooling temperature), and the lower phase containing Ins-PEG-GNPs was transferred to a vial.
[0252] Coupling of PEG3500 and EGFR Ab with GNPs
[0253] To further couple EGFR Ab to the GNPs, 102 μl of HS-PEG-COOH (~3.5 kDa) solution (50 mg / ml) was added to the partially coated GNPs to coat the remaining 15% of the particle surface. The solution was then mixed at 4°C for 2 hours and centrifuged at 14,000 RPM for 30 minutes. EGFR Ab was then covalently coupled to the free carboxyl group of HS-PEG-COOH (~3.5 kDa) by adding excess EGFR Ab along with EDC and NHS. The solution was then stirred at 4°C for 2 hours and centrifuged until a final concentration of 30 mg / ml Au was achieved.
[0254] EGFR & Ins-GNPs were characterized using UV-Vis spectroscopy after each preparation step. Figure 2 Successful coating was confirmed by the migration of UV-Vis signals after different coating levels.
[0255] The covalent coupling between the PEG-linked compound and insulin and EGFR Ab was confirmed by sodium lauryl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Free insulin, free EGFR Ab, GNP, PEG-coated GNP (GNP+PEG), insulin-coated GNP (GNP+PEG+INS), and EGFR&Ins-GNP (GNP+PEG+INS+Ab) were analyzed by SDS-PAGE (run at 120V for 60 minutes). As can be seen in... Figure 3 As observed in the electrophoresis, neither insulin nor EGFRAb separated from GNPs, indicating a stable covalent coupling.
[0256] Example 2: Delivery of EGFR & Ins-GNPs in the mouse brain
[0257] Thirteen male BALB / c mice, each weighing 20–25 g, were randomly divided into three groups. Mice in group 1 (control; n = 3) were administered control GNPs (200 μl; 30 mg / ml) IV. The control GNPs were prepared by coating 20 nm spherical GNPs with a 5 kDa mPEG-SH layer (mPEG-GNPs). Mice in group 2 (n = 5) were administered 200 μl of EGFR-Ins-GNPs intravenously via the tail vein. Mice in group 3 (n = 5) were administered 20 μl of EGFR-Ins-GNPs intranasally. Five hours after administration, all mice were anesthetized and sacrificed. The mice were perfused to remove all particles present in the blood vessels.
[0258] After sacrifice, the mice's brains were scanned using a miniature CT scanner. As can be seen in... Figure 4A As observed, no GNP accumulation was observed in the brains of control mice that received non-targeted mPEG-GNPs. Conversely, miniature CT images of the brains of mice from groups two and three (respectively) showed no GNP accumulation. Figure 4B and 4C It shows a clearly visible accumulation of EGFR & Ins-GNP.
[0259] Further quantitative measurement of GNP accumulation in mouse brains was performed using ICP-MS analysis of mouse brain samples, showing a total amount of 13.45 μg Au (approximately 1.6646E+14 particles according to theoretical calculation) in the brain after intravenous administration and a total amount of 0.42 μg Au (approximately 5.19772E+12 particles according to theoretical calculation) in the brain after intranasal administration.
[0260] In summary, the results indicate that insulin ligands promote the transport of GNP complexes across the BBB, resulting in significant penetration of EGFR&Ins-GNPs into the brain following intravenous or intranasal administration, with a higher amount of particles penetrating the brain via IV administration. However, mini-CT images show that the particles reach different locations when administered via IV or IN. Therefore, these results further suggest that EGFR&Ins-GNPs can act as CT contrast agents for labeling specific brain regions in which they accumulate.
[0261] Example 3: Biodistribution and pharmacokinetic characteristics of EGFR & Ins-GNPs
[0262] To examine the levels and systemic biodistribution of EGFR and Ins-GNPs in the brain, EGFR and Ins-GNPs were intravenously injected into the tail vein of male BALB / c mice. Mice were sacrificed at various time points up to one month after injection (n=3 at each time point), and the brain, kidneys, and livers were harvested for ICP-MS analysis to quantify the amount of gold in the organs over time.
[0263] As in Figure 5A As confirmed in the study, EGFR & Ins-GNPs rapidly accumulate in the brain and remain at high concentrations until 5 hours after injection. Gradual clearance of the particles from the brain was subsequently observed; the amount of gold was negligible one week after injection and completely cleared one month later.
[0264] Furthermore, as can be seen Figure 5B As observed, EGFR & Ins-GNPs accumulate in the kidneys and liver until 24 hours after injection, and are then cleared from these organs until 1 month after injection.
[0265] Example 4: Delivery of IgG1 & Ins-GNPs in the mouse brain
[0266] As described in Example 1, GNPs coated with fluorescent antibody IgG1 (mouse monoclonal IgG1 Alexa Fluor 488 isotype, clone 11711) and insulin (IgG1 & Ins-GNPs) were synthesized, with the following differences:
[0267] 1) Use fluorescent IgG1 antibody instead of EGFR Ab.
[0268] 2) HS-PEG-COOH (~5kDa): Add 193μl instead of 145μl (~20% of particle surface area).
[0269] 3) mPEG-SH (~5kDa): Add 580μl instead of 677μl (~60% of particle surface area).
[0270] 4) HS-PEG-COOH (~3.5kDa): Add 136μl instead of 102μl (~20% of particle surface area).
[0271] Mice were intravenously injected with 200 μl of 30 mg / ml IgG1 & Ins-GNPs (n = 5) or an equivalent amount (0.4 mg) of free fluorescent IgG1 antibody (n = 3). Eight hours after injection, mouse brains were extracted and analyzed using ICP-MS (n = 3) or immunocytochemistry (n = 2).
[0272] As Figure 6AAs confirmed by quantitative ICP-MS analysis, IgG1 & Ins-GNPs successfully penetrated into the brain. Figure 6A ).
[0273] For immunocytochemical fluorescence (IHC F), the fixation and permeabilization method (FPM) used was FPM13, and sections were taken from the cerebral cortex. 7µm frozen brain sections were prepared using Cryostat and immunostained. 4′,6-diamidinyl-2-phenylindole (DAPI) was used for nuclear DNA labeling. The fluorescent antibody signal was detected using confocal microscopy, and images were acquired. All images were taken under the same exposure conditions. As can be seen in... Figure 6B As observed, high fluorescence was observed in brain slices from mice treated with IgG1 & Ins-GNPs (right panel), while no fluorescence was observed in brain slices from mice treated with free fluorescent antibodies except for DAPI signal (left panel). These results indicate that the GNP-targeting system promotes brain penetration of antibodies with naturally limited transBBB transport capabilities.
[0274] Example 5: Delivery of Anti-Iba1 & Ins-GNPs in the Mouse Brain
[0275] GNPs coated with insulin and anti-Iba1 fluorescent antibody (rabbit monoclonal antibody – Alexa fluor 647) were synthesized as described in Example 4, instead of IgG1 Ab, using fluorescent anti-Iba1 (rabbit monoclonal antibody – Alexa fluor 647).
[0276] Mice were intravenously injected with 200 μl of 30 mg / ml Anti-Iba1 & Ins-GNPs or an equivalent amount (0.1 mg) of free fluorescent anti-Iba1. Seven hours after injection, the mice were sacrificed and perfused. The mouse brain sections were then imaged using super-resolution microscopy. Vascular muscles were stained with Alexa Fluor 568, and BBB endothelial cells were stained with CD31–Alexa Fluor 488.
[0277] As can be Figure 7A and 7B The super-resolution microscopy images shown in the images depict the migration of Anti-Iba1 & Ins-GNPs in the brain (7A), while the free antibodies are blocked in the blood vessels of the brain (7B).
[0278] Example 6: Function of antibodies after covalent conjugation to GNP shuttles
[0279] To ensure the antibody retained its function when conjugated to the GNP shuttle, in vitro experiments were performed using an anti-TGF-β antibody, non-hematoxylin and eosin. Upon binding of the non-hematoxylin and eosin with TGF-β cytokines secreted by cancer cells, immune system activity was enhanced, as indicated by an increase in tumor necrosis factor (TNF)-α.
[0280] Non-hematoxylin and eosinogens (&Ins-GNPs) were synthesized using non-hematoxylin and eosinogens instead of EGFR Ab, as described in Example 1.
[0281] F4-T cells were co-cultured with Skmel23 cancer cells containing soluble TGFβ and 1 μM of non-hematoxylin and eosin (Ins-GNPs) were added. After overnight incubation, TNF-α secretion was quantified using ELISA and compared with control cells that did not contain non-hematoxylin and eosin (Ins-GNPs).
[0282] Interestingly, higher concentrations of TNF-α were observed in cells treated with non-hematoxylin and eosin-GNPs compared to untreated cells, indicating that the antibody retained its activity despite being immobilized to the GNP complex via covalent coupling to the PEG linker.
[0283] Example 7: Delivery of peptides & Ins-GNPs in the brain
[0284] To examine the ability of the nanoplatform to deliver peptides to the brain, a cyclic peptide (with the structure presented below) targeting amyloid-β (Aβ) plaques present in the brains of Alzheimer's disease patients was used.
[0285] (Cyclic D,L-α-peptide; US 2017 / 0088585)
[0286] The cyclic peptide (PEP) was coupled to Ins-GNPs to form PEP&Ins-GNPs. The synthesis process was performed as described in Example 1, using a cyclic D,L-α-peptide instead of EGFR-Ab.
[0287] After different coupling steps, UV-Vis spectroscopy was used. Figure 8 Particles were characterized using dynamic light scattering (DLS) and zeta potential measurements.
[0288] Table 1 shows the zeta potential and hydrodynamic diameter of naked GNPs, GNPs+PEG (after the first coupling step), and the final particles coated with insulin and peptides.
[0289] Table 1: Physical characterization of synthetic particles containing cyclic peptides as active pharmaceutical agents
[0290] particle Size (nm) zeta potential (mV) naked GNP 23.4 -38.7 GNP+PEG 45.1 -5.95 GNP+PEGs+INS+peptides 56.3 -0.1
[0291] The decrease in zeta potential to near neutral levels and the increase in particle diameter after particle coating confirmed chemical coating. Furthermore, expanded and migrating UV-Vis signals were observed at different coating levels. Figure 8 ).
[0292] For in vivo experiments, a 5XFAD mouse model of Alzheimer's disease (AD, 4 months old) was used.
[0293] PEP&Ins-GNPs were injected intravenously (200 μl, 25 mg / ml) into the tail veins of 5xFAD mice (n=5) and WT mice (n=5). Six hours after IV injection, the mice were sacrificed, perfused, and scanned using a miniature CT scanner. Figure 9A and 9B As can be seen, after IV administration, PEP&Ins-GNPs penetrated into the brains of both healthy and diseased mice, and interacted with the healthy brain (…). Figure 9A Compared to the previous method, the accumulation in the diseased brain was significantly higher. Figure 9B ).
[0294] The accumulation of PEP & Ins-GNPs in mouse brains was further quantitatively measured by ICP-MS analysis of mouse brain samples. Figure 9C The results showed that PEP&Ins-GNPs accumulated in the brains of AD mice at a rate four times higher than in healthy brains, indicating that these particles were gradually cleared from healthy brains but remained in the brains of AD mice for a longer period due to the coupling peptides targeting Aβ plaques.
[0295] To further investigate the targeting ability of the cyclic peptides, fluorescently labeled PEP&Ins-GNPs were synthesized using rhodamine B-labeled peptides. The fluorescently labeled PEP&Ins-GNPs were incubated with unfixed hippocampal coronal sections from WT or 5xFAD mice at 4°C for 20 hours. The sections were then co-stained with anti-Aβ antibody 6E10 (which recognizes Aβ plaques) and DAPI (for staining cell nuclei). Brain sections from AD mice showed significant PEP&Ins-GNP staining, which co-localized with Aβ plaque staining. Figure 9D ),
[0296] This indicates that the peptide retains its function and targeting ability despite being coupled to the GNP vector.
[0297] Example 8: Delivery of CisPt-Ins-GNPs in the mouse brain
[0298] The ability of the GNP platform to deliver bioactive small molecules into the brain was investigated using cisplatin (CisPt), a chemotherapeutic agent with poor BBB penetration.
[0299] Synthesis of cisplatin + insulin-GNPs
[0300] First, 20 nm spherical GNPs (synthesized as described in Example 1) were partially coated (80% particle surface area) with mPEG-SH (5 kDa; 60% particle surface area) and heterofunctional HS-PEG-COOH (1 kDa; 20% particle surface area). Coupling was performed by adding a mixture of HS-PEG-COOH (39 μl, 50 mg / ml) and mPEG-SH (580 μl, 50 mg / ml) to the GNP solution and mixing for 3 hours. The solution was then centrifuged at 14,000 g for 30 minutes. The precipitate containing PEG-coated GNPs (80% coating) was transferred to a vial. Cisplatin was then covalently coupled to the carboxyl group of HS-PEG-COOH by adding excess cisplatin along with EDC and NHS and mixing at 4 °C for 3 hours. The solution was then centrifuged at 14,000 g for 30 minutes at 4 °C, and the lower phase containing cisplatin-GNPs was transferred to a vial.
[0301] To further couple insulin to the GNPs, HS-PEG-COOH (5kDa) (194μl, 50mg / ml) was added to the partially coated GNPs to coat the remaining 20% of the particle surface. The solution was then mixed at 4°C for 3 hours, followed by centrifugation at 14,000g for 30 minutes at 4°C. Insulin was then covalently coupled to the free carboxyl group of HS-PEG-COOH (5kDa) by adding excess insulin along with EDC and NHS. The solution was then stirred at 4°C for 3 hours and centrifuged until a final concentration of 25mg / ml Au was achieved.
[0302] In vivo experiments
[0303] 6-7 week old male BALB / c mice were administered intravenously via tail vein using 200 μl of cisplatin plus insulin-GNPs (approximately 0.1 mg cisplatin as measured by ICP-MS of Pt concentration) (n=3) or an equivalent dose of free cisplatin (100 μl, 1 mg / ml) (n=3). Mice were sacrificed 8 hours post-administration. The mice were perfused with 20 ml of saline to remove all intravascular particles.
[0304] After sacrifice and perfusion, mouse brains were extracted and weighed, and then analyzed by ICP-MS to quantify the amounts of Au and Pt in the brain.
[0305] As can be Figure 10A and 10B As observed, gold and platinum were simultaneously found in the brains of mice administered cisplatin + insulin-GNPs, indicating that the GNPs were successfully delivered to the brain. Furthermore, Figure 10B The results showed that the amount of Pt found in the brains of mice administered cisplatin + insulin-GNPs was significantly higher than that after administration of an equivalent dose of free cisplatin, indicating that the GNP platform enhances the penetration of small molecule cisplatin into the BBB.
[0306] Further experiments were conducted using similar GNPs (PJ34-Ins-GNPs) coated with PJ34, using insulin and cisplatin as alternative small molecule drugs. Ex vivo micro-CT scans of mouse brains 24 hours after intravenous administration of these particles showed that PJ34-Ins-GNPs penetrated the brain efficiently, providing further evidence for the possibility of delivering small molecule therapeutic agents to the brain using the GNP platform.
[0307] Example 9: Delivery of IgG1 & Ins-coated iron oxide nanoparticles in mouse brain
[0308] 50 nm spherical iron oxide nanoparticles (IONPs) coated with dextran were purchased from Chemical. The dextran coating was first removed from the particles by adding double-distilled water (DDW) and centrifuging at 12,000 RPM for 30 minutes.
[0309] The IONPs were then coated with insulin and IgG1 antibody via HS-PEG-COOH (~5kDa) and HS-PEG-COOH (~3.5kDa), respectively.
[0310] First, the IONPs were partially coated (85% particle surface area) using mPEG-SH (~5kDa; 70% particle surface area) and heterofunctional HS-PEG-COOH (~5kDa; 15% particle surface area). The amounts of mPEG-SH and HS-PEG-COOH required for partial coating were derived theoretically based on particle diameter and surface area. Coupling was performed by adding a mixture of HS-PEG-COOH (58 μl, 50 mg / ml) and mPEG-SH (271 μl, 50 mg / ml) to the IONP solution and mixing for two hours. The solution was then centrifuged, and the PEG-coated IONPs (85% coating in total) were transferred to a vial. Insulin was then covalently coupled to the carboxyl group of HS-PEG-COOH by adding excess insulin along with EDC and NHS on ice and mixing for two hours. The solution was then centrifuged, and the lower phase containing Ins-PEG-IONPs was transferred to a vial.
[0311] For the subsequent coating step, HS-PEG-COOH (~3.5 kDa) (41 μl, 50 mg / ml) was added to the partially coated IONPs to coat the remaining 15% of the particle surface. The solution was then mixed at 4°C for 2 hours and centrifuged. IgG1 was then covalently coupled to the free carboxyl group of HS-PEG-COOH (~3.5 kDa) by adding excess IgG1 along with EDC and NHS. The solution was then stirred at 4°C for 2 hours and centrifuged until a final Fe concentration of 25 mg / ml was achieved.
[0312] In vivo experiments
[0313] Male BALB / c mice (n=3) were intravenously injected with IgG1 & Ins-IONPs (200 μl; 25 mg / ml). Eight hours later, the mice were sacrificed and perfused to remove particles present in the blood vessels. The mouse brains were then extracted, and the accumulation of particles was assessed by quantitatively measuring Fe concentration using ICP-MS analysis.
[0314] The results showed that IgG1 & Ins-IONPs penetrated efficiently into the brain 8 hours after injection, with a Fe concentration of 0.0047 mg Fe / gr in brain tissue. Therefore, it can be concluded that different nanoparticle types, especially IONPs, can be used as the nanoparticle core of the delivery system.
[0315] Example 10: BBB penetration of GNP coated with antibody (IgG1) and transferrin as a component of brain internalization
[0316] GNPs coated with IgG1 and transferrin (IgG1 & Trf-GNPs) were synthesized using IgG1 antibody instead of EGFR Ab and human total transferrin instead of insulin, as described in Example 1.
[0317] To investigate their BBB penetration, in vitro BBB models were used. Human induced pluripotent stem cells (iPSCs) differentiating into BMEC-like cells (iBMECs) provide a robust source of human BBB models. iBMECs exhibit molecular, structural, and functional BBB properties similar to those of the human cerebrovascular system, including transendothelial resistance (TEER). These BBB models utilized 2D Transwell inserts (Vatine, Gad D. et al., Cell stem cell 20.6(2017):831-843; and Lippmann, Ethan S. et al., Scientific reports 4.1(2014):1-10). (Note: The second sentence "GHuman" appears to be a typo and should be "Human".)
[0318] 500,000 cells were cultured and grown in transwells until their TEE value reached approximately 3500 Ω×cm. 2 TEER was measured, and then IgG1&Trf-GNPs, IgG1&Ins-GNPs, or mPEG-GNPs (control particles) were introduced into the upper culture medium (0.25 mg / 1 million cells; n=2 per group). Two hours later, TEER values were measured again and the decrease in TEER was calculated (compared to the initial value before particle addition). A decrease in TEER value indicates lower resistance and suggests increased permeability through the dense cell layer.
[0319] Figure 11 This indicates a decrease in TEER in all three groups. Compared to control GNPs, both IgG1&Trf-GNPs (GNPs+IgG1+Trf) and IgG1&Ins-GNPs (GNPs+IgG1+Ins) showed increased permeability through the dense cellular layer, suggesting that these particles have the potential to penetrate into the brain in vivo due to their coupled brain-internalized components, namely insulin or transferrin. However, compared to transferrin-coupled particles, insulin-coupled particles showed significantly enhanced permeability.
[0320] Example 11: Effects of insulin levels, antibody levels, and linker size on the ability of nanodelivery systems to cross the BBB
[0321] To investigate the effects of linker size and the coverage percentage of each coating molecule on the ability of the nanodelivery system to cross the brain-targeting gold nanoparticles coated with insulin and IgG1 Ab, various brain-targeting gold nanoparticles were synthesized. All particles were synthesized as described in Example 1, except for the MW of the PEG linkers used or their relative amounts (i.e., coverage percentage). Table 2 specifies the different particles prepared and studied.
[0322] Table 2: Particles synthesized using different linker sizes and relative amounts
[0323]
[0324]
[0325] The brain-targeting particles listed in Table 1 were injected intravenously (200 μl, 30 mg / ml) into the tail vein of male Balb / C mice (n=2 per group). Eight hours after injection, the mice were sacrificed and perfused. The brains were then extracted and analyzed by ICP-MS to quantify the amount of gold crossing the BBB.
[0326] Figure 12AThe effect of insulin levels on the ability of particles to penetrate into the brain was demonstrated. It can be seen that coating GNPs with insulin at a coverage of 5% to 10% is insufficient to deliver a significant amount of administered particles into the brain. However, coating particles with insulin at a coverage of 15% or 20% results in significant brain penetration. Surprisingly, GNPs coated with a higher concentration, i.e., 50% insulin, exhibited significantly lower penetration into the brain. This result is presumably attributed to steric hindrance and structural constraint.
[0327] Figure 12B The effect of antibody levels in a nanodelivery system on its ability to penetrate the brain was demonstrated. It can be seen that among particles with different antibody levels, GNPs with 20% antibody coating exhibited the highest brain penetration, while particles with higher antibody levels showed lower brain penetration. However, it should be noted that although 40% antibody coating resulted in lower penetration for GNPs compared to 20% antibody coating, the total amount of antibodies penetrating into the brain was higher when using these particles due to the higher antibody concentration per particle.
[0328] Figure 12C The effect of linker length on the ability of particles to penetrate into the brain was demonstrated. It can be seen that the highest brain penetration was achieved when PEG5000 and PEG3500 were used for insulin and antibody conjugation, respectively. Interestingly, low brain penetration was obtained when linkers of similar sizes were used for insulin and antibody conjugation (including linkers with relatively low and high MW, i.e., MW = 458 Da, 1000 kDa, and 3500 kDa PEG linkers). Similarly, low brain penetration was obtained when PEG1000 and PEG3500 were used for insulin and antibody conjugation, respectively. These results suggest that for efficient penetration into the brain through the BBB, insulin, which is a component of brain internalization, should be exposed on the surface of the entire nanodelivery system (i.e., it should be present on the outer surface of the particle shell). Since insulin is significantly smaller than antibodies (5 kDa vs. 150 kDa), it must be conjugated to a linker that is longer than the linker used for antibody binding in order to remain exposed on the surface of the nanodelivery system and not be shielded by the antibody.
[0329] Interestingly, significant brain penetration was achieved when the antibody and insulin were conjugated to 5kDa and 1kDa PEG linkers, respectively (though less than that obtained using Ins-PEG5000-Ab-PEG3500). Without being limited by theories or mechanisms of action, this result can be explained by the potential folding of the 5kDa PEG linker, resulting in a shorter actual length (i.e., end-to-end distance), thus exposing the insulin components.
[0330] Although the invention has been described in conjunction with specific embodiments thereof, it will be apparent to those skilled in the art that many alternatives, modifications, and variations will be readily apparent. Therefore, it is intended to cover all such alternatives, modifications, and variations falling within the spirit and broad scope of the appended claims.
Claims
1. A nanodelivery system comprising: (a) Inorganic nanoparticles, which are combined with a first linear polymeric linker and a second linear polymeric linker having different lengths. The molecular weight of the first linear polymer linker is at least 1000 Da higher than the molecular weight of the second linear polymer linker; The second linear polymeric linker has a molecular weight of at least 1000 Da, and the first and second linear polymeric linkers are indestructible under physiological conditions; the first and second linear polymeric linkers are polyethylene glycol; and the molecular weight of the first linear polymeric linker is in the range of 2000-7000 Da. (b) a brain-mediated transporter component, which is coupled to the first linear polymeric linker; and (c) An active pharmaceutical agent selected from bioactive molecules or labeled molecules, wherein the pharmaceutical agent is coupled to the second linear polymer linker; The first linear polymeric linker is added in an amount suitable for covering the surface of the inorganic nanoparticles, between 15% and 20%.
2. The nanodelivery system according to claim 1, wherein the molecular weight of the first linear polymeric linker is higher than the molecular weight of the second linear polymeric linker.
3. The nanodelivery system according to claim 1 or 2, wherein the first linear polymeric linker is composed of repeating monomer units, and the second linear polymeric linker is composed of the same repeating monomer units as the first linear polymeric linker, and wherein the first linear polymeric linker has a different number of repeating monomer units than the second linear polymeric linker.
4. The nanodelivery system according to claim 1 or 2, wherein the brain-mediated transporter component is covalently coupled to the linker via a first terminal functional group of the first linear polymer linker, and the active agent is covalently coupled to the linker via a second terminal functional group of the second linear polymer linker.
5. The nanodelivery system of claim 4, wherein the first terminal functional group and the second terminal functional group are the same.
6. The nanodelivery system according to claim 1 or 5, wherein the inorganic nanoparticles are bound to the second linear polymeric linker via sulfur bonds, and the active agent is coupled to the second linear polymeric linker via amide bonds.
7. The nanodelivery system according to claim 1 or 2, wherein the first linear polymeric linker accounts for 5% mol to 60% mol of the total polymeric linker bound to the inorganic nanoparticles.
8. The nanodelivery system according to claim 1 or 2, wherein the active agent is a bioactive molecule.
9. The nanodelivery system according to claim 1 or 2, wherein the active pharmaceutical agent is selected from macromolecules, peptides, small molecules, oligonucleotides, antisense RNA, and any combination thereof.
10. The nanodelivery system of claim 9, wherein the macromolecule is an antibody.
11. The nanodelivery system according to claim 1 or 2, wherein the first linear polymeric linker accounts for 10% mol to 40% mol of the total polymeric linker bound to the inorganic nanoparticles.
12. The nanodelivery system according to claim 1 or 2, wherein the second linear polymeric linker accounts for 5% mol to 60% mol of the total polymeric linker bound to the inorganic nanoparticles.
13. The nanodelivery system according to claim 1 or 2, wherein the polyethylene glycol PEG is selected from thiolized PEG acid HS-PEG-COOH and thiolized PEG amine HS-PEG-NH2, wherein the thiolized end is bound to the inorganic nanoparticles and the acid or amine end is coupled to the brain-mediated transport protein component or the active agent.
14. The nanodelivery system of claim 1 or 2, further comprising a third polymeric linker bound to the inorganic nanoparticles, wherein the third polymeric linker is single-function.
15. The nanodelivery system of claim 14, wherein the third polymeric linker comprises a polymer selected from: polyethers, polyacrylates, polyanhydrides, polyvinyl alcohol, polysaccharides, poly(N-vinylpyrrolidone), polyglycerol (PG), poly(N-(2-hydroxypropyl)methacrylamide), polyoxazoline, poly(amino acid)-based hybrids, recombinant peptides, derivatives thereof, and combinations thereof.
16. The nanodelivery system of claim 15, wherein the third polymeric linker comprises a polyether, wherein the polyether is methoxy polyethylene glycol (mPEG).
17. The nanodelivery system according to claim 1 or 2, wherein the inorganic nanoparticles are selected from metal nanoparticles, metal oxide nanoparticles, ceramic nanoparticles, and any combination thereof.
18. The nanodelivery system of claim 17, wherein the metal is selected from gold, silver, platinum, iron and any combination thereof, and / or wherein the metal oxide is selected from iron oxide, magnesium oxide, nickel oxide, cobalt oxide, aluminum oxide, zinc oxide, copper oxide, manganese oxide and any combination thereof.
19. The nanodelivery system according to claim 1 or 2, wherein the inorganic nanoparticles are selected from gold, iron(III) oxide, and iron(II,III) oxide.
20. The nanodelivery system of claim 1 or 2, wherein the brain-mediated transporter component is selected from: insulin, an antibody specifically targeting the insulin receptor, transferrin, an antibody specifically targeting the transferrin receptor, a polypeptide specifically binding to the transferrin receptor, a polypeptide specifically binding to the insulin receptor, insulin-like growth factor 1, an antibody specifically targeting the insulin-like growth factor receptor 1, a polypeptide specifically binding to the insulin-like growth factor receptor 1, apolipoprotein A1, B, or E, lactoferrin, angiopep-2, low-density lipoprotein, an antibody specifically targeting the low-density lipoprotein receptor or lipoprotein receptor-associated protein, a polypeptide specifically binding to the low-density lipoprotein receptor or lipoprotein receptor-associated protein, an antibody specifically targeting the diphtheria toxin receptor, a polypeptide specifically binding to the diphtheria toxin receptor, BBB-penetrating cell-penetrating peptide (CPP), and any combination thereof.
21. The nanodelivery system of claim 20, wherein the brain-mediated transporter component is insulin.
22. The nanodelivery system according to claim 1 or 2, wherein the inorganic nanoparticles have a diameter of 10-160 nm.
23. The nanodelivery system according to claim 1 or 2, wherein the inorganic nanoparticles have a diameter of 12 to 70 nm.
24. A method for preparing a nanodelivery system according to any one of claims 1 to 23, the method comprising the following sequential steps: a) The surface of the inorganic nanoparticles is partially coated with the first linear polymeric linker, and then the first linear polymeric linker is coupled to the brain-mediated transporter component; and b) Partially coat the surface of the inorganic nanoparticles with the second linear polymeric linker, and then couple the second linear polymeric linker to the active pharmaceutical ingredient. Steps (a) and (b) can be performed in any order.
25. The method of claim 24, wherein the first linear polymeric linker has a first terminal functional group configured to bind the brain-mediated transporter component, and the second linear polymeric linker has a second terminal functional group configured to bind the active agent, and wherein the first and second functional groups are identical.
26. The method of claim 24 or 25, further comprising partially coating the surface of the inorganic nanoparticles with a third polymeric linker, wherein the polymeric linker is a single-function linker.
27. The method according to claim 24 or 25, wherein the active agent is an antibody or peptide, and wherein step (a) is performed prior to step (b).
28. The method according to claim 24 or 25, wherein the active pharmaceutical agent is a small molecule, and wherein step (a) is performed after step (b).
29. The method of claim 24 or 25, wherein the second linear polymeric linker is added in an amount between 5% and 60% suitable for covering the surface of the inorganic nanoparticles.
30. A pharmaceutical composition comprising the nanodelivery system and pharmaceutically acceptable carrier as described in any one of claims 1 to 23.
31. The pharmaceutical composition of claim 30, wherein it is formulated for at least one of intravenous (IV), intranasal (IN), and intrathecal (IT) administration.
32. The pharmaceutical composition of claim 30 or 31, for use in the prevention, treatment and / or monitoring of brain-related diseases or disorders in subjects of need.
33. Use of the pharmaceutical composition of claim 30 or claim 31 in the preparation of a medicament for the prevention, treatment and / or monitoring of brain-related diseases or disorders in subjects in need.
34. The use according to claim 33, further comprising the step of imaging the brain of the subject to assess the accumulation of the nanodelivery system in the subject's brain.
35. The use according to claim 34, wherein the imaging is performed using an imaging system selected from: computed tomography (CT), X-ray imaging, magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT), ultrasound (US), and any combination thereof.
